<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Rep</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Rep</journal-id><journal-id journal-id-type="pmc-domain-id">2242</journal-id><journal-id journal-id-type="pmc-domain">infectdisreps</journal-id><journal-id journal-id-type="publisher-id">idr</journal-id><journal-title-group><journal-title>Infectious Disease Reports</journal-title></journal-title-group><issn pub-type="ppub">2036-7430</issn><issn pub-type="epub">2036-7449</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12193398</article-id><article-id pub-id-type="pmcid-ver">PMC12193398.1</article-id><article-id pub-id-type="pmcaid">12193398</article-id><article-id pub-id-type="pmcaiid">12193398</article-id><article-id pub-id-type="pmid">40559192</article-id><article-id pub-id-type="doi">10.3390/idr17030061</article-id><article-id pub-id-type="publisher-id">idr-17-00061</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Advances in the Treatment of Enterovirus-D68 and Rhinovirus Respiratory Infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Rahajamanana</surname><given-names initials="VL">Vonintsoa L.</given-names></name><xref rid="af1-idr-17-00061" ref-type="aff">1</xref><xref rid="af2-idr-17-00061" ref-type="aff">2</xref><xref rid="af3-idr-17-00061" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7293-7623</contrib-id><name name-style="western"><surname>Th&#233;riault</surname><given-names initials="M">Mathieu</given-names></name><xref rid="af1-idr-17-00061" ref-type="aff">1</xref><xref rid="af2-idr-17-00061" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rabezanahary</surname><given-names initials="H">Henintsoa</given-names></name><xref rid="af1-idr-17-00061" ref-type="aff">1</xref><xref rid="af2-idr-17-00061" ref-type="aff">2</xref><xref rid="af3-idr-17-00061" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-1873-0161</contrib-id><name name-style="western"><surname>Sahnoun</surname><given-names initials="YG">Yesmine G.</given-names></name><xref rid="af1-idr-17-00061" ref-type="aff">1</xref><xref rid="af2-idr-17-00061" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3633-8017</contrib-id><name name-style="western"><surname>Mallet</surname><given-names initials="MC">Maria Christina</given-names></name><xref rid="af1-idr-17-00061" ref-type="aff">1</xref><xref rid="af2-idr-17-00061" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Isabel</surname><given-names initials="S">Sandra</given-names></name><xref rid="af1-idr-17-00061" ref-type="aff">1</xref><xref rid="af2-idr-17-00061" ref-type="aff">2</xref><xref rid="af4-idr-17-00061" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3986-5146</contrib-id><name name-style="western"><surname>Trottier</surname><given-names initials="S">Sylvie</given-names></name><xref rid="af1-idr-17-00061" ref-type="aff">1</xref><xref rid="af2-idr-17-00061" ref-type="aff">2</xref><xref rid="af3-idr-17-00061" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1230-0735</contrib-id><name name-style="western"><surname>Baz</surname><given-names initials="M">Mariana</given-names></name><xref rid="af1-idr-17-00061" ref-type="aff">1</xref><xref rid="af2-idr-17-00061" ref-type="aff">2</xref><xref rid="af3-idr-17-00061" ref-type="aff">3</xref><xref rid="c1-idr-17-00061" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>&#268;ivljak</surname><given-names initials="R">Rok</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-idr-17-00061"><label>1</label>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Qu&#233;bec-Universit&#233; Laval, Quebec City, QC G1V 0E8, Canada; <email>vonintsoa-lalaina.rahajamanana@crchudequebec.ulaval.ca</email> (V.L.R.); <email>mathieu.theriault@crchudequebec.ulaval.ca</email> (M.T.); <email>henintsoa.rabezanaha@crchudequebec.ulaval.ca</email> (H.R.); <email>yesmine.sahnoun@crchudequebec.ulaval.ca</email> (Y.G.S.); <email>maria-christina.mallet@crchudequebec.ulaval.ca</email> (M.C.M.); <email>sandra.isabel@crchudequebec.ulaval.ca</email> (S.I.); <email>sylvie.trottier@crchudequebec.ulaval.ca</email> (S.T.)</aff><aff id="af2-idr-17-00061"><label>2</label>Centre de Recherche en Infectiologie, Universit&#233; Laval, Quebec City, QC G1V 0E8, Canada</aff><aff id="af3-idr-17-00061"><label>3</label>D&#233;partement de Microbiologie-Infectiologie et d&#8217;Immunologie, Facult&#233; de M&#233;decine, Universit&#233; Laval, Quebec City, QC G1V 0A6, Canada</aff><aff id="af4-idr-17-00061"><label>4</label>D&#233;partement de P&#233;diatrie, Facult&#233; de M&#233;decine, Universit&#233; Laval, Qu&#233;bec City, QC G1V 0A6, Canada</aff><author-notes><corresp id="c1-idr-17-00061"><label>*</label>Correspondence: <email>mariana.baz@crchudequebec.ulaval.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">489151</issue-id><elocation-id>61</elocation-id><history><date date-type="received"><day>31</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>16</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>25</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-26 18:25:14.660"><day>26</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="idr-17-00061.pdf"/><abstract><p>Background/Objectives: Enterovirus-D68 (EV-D68) and rhinoviruses are major contributors to respiratory illnesses in children, presenting a spectrum of clinical manifestations ranging from asymptomatic cases to severe lower respiratory tract infections. No specific antiviral treatments are currently approved for these viruses. Method: We conducted a comprehensive literature review of antiviral agents investigated for EV-D68 and rhinovirus infections. Results: Several antiviral candidates are under investigation, each targeting distinct stages of the viral replicative cycle. Capsid-binding agents and monoclonal antibodies prevent viral attachment by blocking receptor-virus interactions. Inhibitors of viral replication proteins disrupt polyprotein processing and replication organelle biogenesis by targeting non-structural viral proteins. Host factor inhibitors impair viral attachment, replication organelle formation, or RNA replication by interfering with critical host pathways. Conclusions: While no specific antivirals are yet approved for EV-D68 and rhinovirus infections, emerging therapeutic candidates offer potential avenues for treatment. Continued preclinical and clinical investigation will be essential to validate these approaches and expand the available options for affected patients.</p></abstract><kwd-group><kwd>rhinovirus</kwd><kwd>enterovirus</kwd><kwd>EV-D68</kwd><kwd>respiratory infection</kwd><kwd>antivirals</kwd></kwd-group><funding-group><award-group><funding-source>Canada First Research Excellence Fund</funding-source><award-id>134482</award-id></award-group><award-group><funding-source>Canada Research Chair</funding-source><award-id>CRC-2022-00103</award-id></award-group><award-group><funding-source>Postdoctoral Mobility Fellowship from the Swiss National Science Foundation</funding-source><award-id>P500PM_221971</award-id></award-group><award-group><funding-source>Centre de recherche du CHU de Qu&#233;bec&#8212;Universit&#233; Laval infrastructure</funding-source></award-group><award-group><funding-source>Infectious Research Center at Universite Laval and the World Citizens Scholarship&#8212;Excellence section, Universite Laval</funding-source></award-group><award-group><funding-source>Lung Health Foundation Emerging Scholar Research Award</funding-source></award-group><award-group><funding-source>FRQS</funding-source></award-group><funding-statement>M.B. was supported by the Sentinel North Research Chair at Universit&#233; Laval (SN 134482, funded by the Canada First Research Excellence Fund) and the Canada Research Chair (CRC-2022-00103). The FRQS supports the Centre de recherche du CHU de Qu&#233;bec&#8212;Universit&#233; Laval infrastructure. V.L.R. was partially supported by a scholarship from the Infectious Research Center at Universite Laval and the World Citizens Scholarship&#8212;Excellence section, Universite Laval. Y.S. was supported by a Lung Health Foundation Emerging Scholar Research Award to S.I. S.I. received the Clinical Research Scholars Junior 1 from FRQS. M.C.M. was supported by a Postdoctoral Mobility Fellowship from the Swiss National Science Foundation (P500PM_221971).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-idr-17-00061"><title>1. Background</title><p>Enterovirus (EV) and rhinovirus (RV) species commonly infect humans. They cause a wide range of clinical manifestations across all age groups: asymptomatic, upper and lower respiratory infections, aseptic meningitis, viral encephalitis, myopericarditis, acute flaccid myelitis (AFM), hand, foot and mouth disease, herpangina, viral conjunctivitis, to name a few [<xref rid="B1-idr-17-00061" ref-type="bibr">1</xref>,<xref rid="B2-idr-17-00061" ref-type="bibr">2</xref>]. They impose an important socioeconomic burden, resulting in significant healthcare expenses and productivity losses [<xref rid="B3-idr-17-00061" ref-type="bibr">3</xref>].</p><p>The name enterovirus comes from the Greek word &#8220;<italic toggle="yes">enteron</italic>&#8221;, meaning intestine, and the latin word &#8220;<italic toggle="yes">virus</italic>&#8221; meaning poison [<xref rid="B4-idr-17-00061" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00061" ref-type="bibr">5</xref>]. While traditionally linked to enteric transmission, certain EVs, such as EV-D68, primarily spread through respiratory routes [<xref rid="B6-idr-17-00061" ref-type="bibr">6</xref>]. In 2014, EV-D68 triggered an outbreak of severe lower respiratory tract infections across North America, predominantly affecting children. This outbreak was also associated with AFM, a serious neurological complication [<xref rid="B7-idr-17-00061" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00061" ref-type="bibr">8</xref>]. The increasing number of outbreaks since 2014 suggests a high potential for this virus to emerge as a significant human pathogen [<xref rid="B7-idr-17-00061" ref-type="bibr">7</xref>,<xref rid="B9-idr-17-00061" ref-type="bibr">9</xref>].</p><p>Rhinovirus, whose prefix comes from the Greek word &#8220;<italic toggle="yes">rhis</italic>&#8221;, meaning nose, is a group of viruses linked to respiratory illnesses [<xref rid="B10-idr-17-00061" ref-type="bibr">10</xref>]. While widely recognized as the primary cause of the common cold, their role in severe illnesses has often been overlooked [<xref rid="B11-idr-17-00061" ref-type="bibr">11</xref>]. In adults, growing evidence over the past few decades has linked RVs to asthma and chronic obstructive pulmonary disease exacerbations [<xref rid="B12-idr-17-00061" ref-type="bibr">12</xref>,<xref rid="B13-idr-17-00061" ref-type="bibr">13</xref>,<xref rid="B14-idr-17-00061" ref-type="bibr">14</xref>,<xref rid="B15-idr-17-00061" ref-type="bibr">15</xref>,<xref rid="B16-idr-17-00061" ref-type="bibr">16</xref>,<xref rid="B17-idr-17-00061" ref-type="bibr">17</xref>,<xref rid="B18-idr-17-00061" ref-type="bibr">18</xref>]. In children with underlying conditions such as prematurity, heart disease, or metabolic disorders, RV infections may result in severe outcomes leading to higher hospitalization rates and requiring intensive care [<xref rid="B19-idr-17-00061" ref-type="bibr">19</xref>,<xref rid="B20-idr-17-00061" ref-type="bibr">20</xref>].</p><p>A deeper understanding of these viruses is essential for developing effective preventive and therapeutic strategies, particularly for vulnerable populations, and to improve outbreak preparedness. This review provides a comprehensive overview of developing antiviral agents for EV-D68 and RVs, examining both historically studied antiviral approaches and those currently under investigation.</p></sec><sec id="sec2-idr-17-00061"><title>2. Enterovirus Classification</title><p>EVs and RVs are classified within the singular genus <italic toggle="yes">Enterovirus</italic>, under the <italic toggle="yes">Picornaviridae</italic> family, as confirmed by genomic and antigenic analyses [<xref rid="B21-idr-17-00061" ref-type="bibr">21</xref>]. Historically, EVs were classified into polioviruses, coxsackieviruses (A/B), and echoviruses serotypes defined by antigenic properties observed through antibody neutralization tests. However, overlapping biological properties led to a revised system using consecutive numbering supported by genotyping (e.g., EV-A71, EV-D68) [<xref rid="B22-idr-17-00061" ref-type="bibr">22</xref>]. Genotype classification relies on the genetic sequence analysis of the protein VP1, a key component of the viral capsid region [<xref rid="B23-idr-17-00061" ref-type="bibr">23</xref>]. Classification now prioritizes genetic lineage over serogroups and genotyping of VP1 has become the gold standard for EV classification, providing a more robust framework for understanding viral diversity and evolution.</p><p>At present, the <italic toggle="yes">Enterovirus</italic> genus comprises 15 species: 12 EV species (A&#8211;L) and 3 RV species (A&#8211;C). Of these, 7 species are human pathogens, including EV A&#8211;D and RV A&#8211;C (<xref rid="idr-17-00061-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B4-idr-17-00061" ref-type="bibr">4</xref>]. EV-D68 is now part of the EV-D species, which includes five genotypes (EV-D68, EV-D70, EV-D94, EV-D111, and EV-D120), each linked to distinct symptoms [<xref rid="B24-idr-17-00061" ref-type="bibr">24</xref>].</p></sec><sec id="sec3-idr-17-00061"><title>3. Virological Characteristics</title><p>EVs are positive-sense single-stranded RNA viruses with a genome of approximately 7500 nucleotides [<xref rid="B25-idr-17-00061" ref-type="bibr">25</xref>]. The genome is packaged in small icosahedral capsids measuring approximately 30 nanometers in diameter, composed of 60 copies of four proteins: VP1, VP2, VP3, and VP4 [<xref rid="B26-idr-17-00061" ref-type="bibr">26</xref>]. These proteins are organized into subunits, with VP1-VP3 positioned on the outside and VP4 on the inside, joining at the apexes to create a pattern of alternating trimer in a pentamer symmetry (<xref rid="idr-17-00061-f002" ref-type="fig">Figure 2</xref>).</p><p>Next to the pentavalent apex, a canyon, a circular depression encircling the fivefold axis of symmetry on the virion surface, is thought to contribute significantly to receptor binding [<xref rid="B27-idr-17-00061" ref-type="bibr">27</xref>]. At the base of the canyon, the hydrophobic pocket of each VP1 subunit houses a host-derived lipid &#8220;pocket factor&#8221;, target of some antiviral molecules [<xref rid="B26-idr-17-00061" ref-type="bibr">26</xref>].</p><p>The viral genome consists of three segments (<xref rid="idr-17-00061-f003" ref-type="fig">Figure 3</xref>): a 700&#8211;825 nucleotide long 5&#8242; untranslated region (UTR), a single open reading frame (ORF) that encodes a viral polyprotein, and a 75&#8211;100 nucleotide long 3&#8242; UTR. This polyprotein is cleaved by autocatalysis to produce four structural proteins (VP1&#8211;VP4) and seven non-structural proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D) [<xref rid="B28-idr-17-00061" ref-type="bibr">28</xref>]. The 5&#8242; UTR contains the internal ribosome entry site (IRES), which is essential to recruit ribosomes for the initiation of translation [<xref rid="B29-idr-17-00061" ref-type="bibr">29</xref>]. EVs and RVs exhibit high mutation rates and frequent recombination, particularly in the 5&#8242;UTR-capsid junction and at the beginning of the P2 region, contributing to their genetic diversity and evolution [<xref rid="B30-idr-17-00061" ref-type="bibr">30</xref>].</p></sec><sec id="sec4-idr-17-00061"><title>4. Replicative Cycle</title><p>The replication of the <italic toggle="yes">Enterovirus</italic> genus occurs in the cytoplasm and involves several key steps (<xref rid="idr-17-00061-f004" ref-type="fig">Figure 4</xref>). The cycle begins with viral entry, during which the virus binds to specific cellular receptors and is internalized [<xref rid="B31-idr-17-00061" ref-type="bibr">31</xref>]. Viral uncoating is triggered by the acidic environment of the endosome, where a lower pH causes the release of the viral genome into the cytoplasm [<xref rid="B32-idr-17-00061" ref-type="bibr">32</xref>]. The viral RNA genome is covalently linked to VPg (3B), a viral protein that acts as both a primer for replication and a facilitator of translation. The viral RNA is subsequently translated into a single polyprotein [<xref rid="B28-idr-17-00061" ref-type="bibr">28</xref>,<xref rid="B33-idr-17-00061" ref-type="bibr">33</xref>]. This process occurs as the virus hijacks the host cell&#8217;s ribosomes, which bind to the viral IRES in the 5&#8242;-UTR to initiate protein translation. The polyprotein is cleaved by the viral proteases 2A, 3C, and its precursor form 3CD into four structural proteins (VP1&#8211;VP4) and seven non-structural replication proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D) [<xref rid="B21-idr-17-00061" ref-type="bibr">21</xref>,<xref rid="B34-idr-17-00061" ref-type="bibr">34</xref>,<xref rid="B35-idr-17-00061" ref-type="bibr">35</xref>].</p><p>A crucial aspect of <italic toggle="yes">Enterovirus</italic> replication is the formation of specialized membrane structures called replication organelles (ROs), which are derived from the endoplasmic reticulum and Golgi apparatus, with viral proteins 2B, 2C, and 3A playing key roles in their biogenesis [<xref rid="B33-idr-17-00061" ref-type="bibr">33</xref>,<xref rid="B36-idr-17-00061" ref-type="bibr">36</xref>]. Replication of viral RNA occurs within these ROs, where a favorable lipid environment is created by the viral proteins 2B, 2C, and 3A, assisted by host proteins such as acyl-CoA-binding domain-containing protein (ACBD3), phosphatidylinositol 4-kinase-III&#946; (PI4KIII&#946;), oxysterol-binding protein (OSBP), and OSBP-related protein 4 (ORP4) [<xref rid="B37-idr-17-00061" ref-type="bibr">37</xref>]. Replication begins with the transcription of the genomic (+) RNA into (&#8722;) RNA by the RNA-dependent RNA polymerase (3Dpol), and the (&#8722;) RNA then serves as a template for the synthesis of new (+) RNA [<xref rid="B21-idr-17-00061" ref-type="bibr">21</xref>]. Throughout this process, the virus exploits various host cell pathways and factors. The secretory pathway and autophagy are hijacked to support RO formation [<xref rid="B37-idr-17-00061" ref-type="bibr">37</xref>]. Lipid metabolism is altered, with lipid droplets potentially serving as lipid sources for RO proliferation [<xref rid="B33-idr-17-00061" ref-type="bibr">33</xref>,<xref rid="B37-idr-17-00061" ref-type="bibr">37</xref>]. Host factors such as heat shock proteins (e.g., HSPA9) are recruited to assist in viral protein folding and stabilization [<xref rid="B28-idr-17-00061" ref-type="bibr">28</xref>].</p><p>The replication cycle concludes with the assembly of newly synthesized viral RNA into capsids formed by structural proteins (VP1, VP2, VP3, and VP4). This process involves the encapsidation of RNA into capsid proteins, which self-organize into protomers and pentamers, followed by maturation in cellular structures called autophagosomes [<xref rid="B38-idr-17-00061" ref-type="bibr">38</xref>]. Finally, mature virions are released from the host cell, either through exocytosis, budding, or cell lysis [<xref rid="B39-idr-17-00061" ref-type="bibr">39</xref>].</p><p>The virus replication cycle generates virions within a few hours of the initial infection, with viral RNA replication beginning 2&#8211;3 h post-infection and translation starting shortly after at 3&#8211;4 h [<xref rid="B28-idr-17-00061" ref-type="bibr">28</xref>,<xref rid="B40-idr-17-00061" ref-type="bibr">40</xref>]. Most viral proteins reach high levels between 4 and 7 h post-infection, and new virions are typically released within 8&#8211;10 h, completing the efficient replication cycle of enteroviruses [<xref rid="B41-idr-17-00061" ref-type="bibr">41</xref>,<xref rid="B42-idr-17-00061" ref-type="bibr">42</xref>]. This efficient process, coupled with the virus&#8217;s ability to manipulate host cell machinery, contributes to the pathogenicity and rapid dissemination of <italic toggle="yes">Enterovirus</italic> infections.</p></sec><sec id="sec5-idr-17-00061"><title>5. Current Strategies in <italic toggle="yes">Enterovirus</italic> Antiviral Research</title><p>The biodiverse <italic toggle="yes">Enterovirus</italic> species pose unique challenges due to their ability to mutate rapidly, evade immune responses, and cause widespread outbreaks. EV-D68 exemplifies these concerns, having caused a large epidemic in North America in 2014, with concurrent outbreaks and sporadic cases also reported in Europe, Asia, Australia, and other regions, highlighting its global public health relevance [<xref rid="B43-idr-17-00061" ref-type="bibr">43</xref>,<xref rid="B44-idr-17-00061" ref-type="bibr">44</xref>,<xref rid="B45-idr-17-00061" ref-type="bibr">45</xref>,<xref rid="B46-idr-17-00061" ref-type="bibr">46</xref>,<xref rid="B47-idr-17-00061" ref-type="bibr">47</xref>,<xref rid="B48-idr-17-00061" ref-type="bibr">48</xref>,<xref rid="B49-idr-17-00061" ref-type="bibr">49</xref>]. Epidemiological surveillance reveals a pronounced biennial cycle of incidence peaks during summer and fall, leading to waves of medical consultations [<xref rid="B50-idr-17-00061" ref-type="bibr">50</xref>,<xref rid="B51-idr-17-00061" ref-type="bibr">51</xref>,<xref rid="B52-idr-17-00061" ref-type="bibr">52</xref>].</p><p>Currently, no approved antiviral treatment or vaccine exists for EV or RV infections, leaving supportive care as the primary management strategy [<xref rid="B9-idr-17-00061" ref-type="bibr">9</xref>,<xref rid="B44-idr-17-00061" ref-type="bibr">44</xref>,<xref rid="B50-idr-17-00061" ref-type="bibr">50</xref>,<xref rid="B53-idr-17-00061" ref-type="bibr">53</xref>,<xref rid="B54-idr-17-00061" ref-type="bibr">54</xref>,<xref rid="B55-idr-17-00061" ref-type="bibr">55</xref>]. Developing effective antiviral therapies requires a deep understanding of viral biology, host interactions, and infection mechanisms. This process depends on creating accurate experimental models and designing treatments that are both broad-spectrum and adaptable to viral evolution.</p><sec id="sec5dot1-idr-17-00061"><title>5.1. Experimental Models</title><p>Accurate experimental models are essential for studying <italic toggle="yes">Enterovirus</italic> because they provide insights into viral pathogenesis, host immune responses, and therapeutic efficacy that cannot be fully replicated otherwise. Understanding how these viruses cause disease requires models that mimic human infection. They provide the means to identify viral tropism, replication mechanisms, and host factors contributing to disease severity. Additionally, animal models are critical for testing antiviral drugs and vaccines, ensuring their safety and efficacy before clinical trials.</p><p>In this regard, cell cultures are the primary in vitro models for studying viral activity, pathogenesis, and host interactions [<xref rid="B56-idr-17-00061" ref-type="bibr">56</xref>,<xref rid="B57-idr-17-00061" ref-type="bibr">57</xref>,<xref rid="B58-idr-17-00061" ref-type="bibr">58</xref>]. Human organoids, such as lung organoids, provide human-relevant systems for modelling infections and offering insights into viral tropism and replication in tissue-specific contexts [<xref rid="B59-idr-17-00061" ref-type="bibr">59</xref>,<xref rid="B60-idr-17-00061" ref-type="bibr">60</xref>]. Animal models are then used for studying the infection within a complex organism. Mouse models for rhinovirus (RV) infection have historically been challenging due to species-specific receptor differences [<xref rid="B61-idr-17-00061" ref-type="bibr">61</xref>]. However, recent advances have enabled the development of more useful models. Transgenic mice (<italic toggle="yes">Mus musculus</italic>) (e.g., ICAM-1) and neonatal mice are widely used to replicate human-like symptoms, including neurological and systemic manifestations, and to evaluate vaccines [<xref rid="B62-idr-17-00061" ref-type="bibr">62</xref>,<xref rid="B63-idr-17-00061" ref-type="bibr">63</xref>]. Rodent models, particularly mice, have been extensively used to study <italic toggle="yes">Enterovirus</italic> infection, viral-induced exacerbation of lung diseases, and for testing antivirals and vaccines [<xref rid="B63-idr-17-00061" ref-type="bibr">63</xref>,<xref rid="B64-idr-17-00061" ref-type="bibr">64</xref>,<xref rid="B65-idr-17-00061" ref-type="bibr">65</xref>,<xref rid="B66-idr-17-00061" ref-type="bibr">66</xref>,<xref rid="B67-idr-17-00061" ref-type="bibr">67</xref>]. Despite their high cost, ferrets (<italic toggle="yes">Mustela putorius furo</italic>) and non-human primates are also used due to their close genetic and physiological similarity to humans [<xref rid="B68-idr-17-00061" ref-type="bibr">68</xref>,<xref rid="B69-idr-17-00061" ref-type="bibr">69</xref>,<xref rid="B70-idr-17-00061" ref-type="bibr">70</xref>]. Together, these models offer comprehensive frameworks for understanding <italic toggle="yes">Enterovirus</italic> pathogenesis, testing antivirals and developing vaccines.</p></sec><sec id="sec5dot2-idr-17-00061"><title>5.2. Broad-Spectrum and Adaptable Treatments</title><p>Broad-spectrum antiviral approaches aim to target a wide range of viruses by interfering with essential viral or host processes required for replication, rather than focusing on a single virus or viral family [<xref rid="B71-idr-17-00061" ref-type="bibr">71</xref>]. These strategies include both direct-acting antivirals and host-targeted therapies [<xref rid="B72-idr-17-00061" ref-type="bibr">72</xref>]. Examples of the former include nucleoside analogues like ribavirin, which inhibit viral polymerases across multiple RNA and DNA viruses, and favipiravir, which targets the RNA-dependent RNA polymerase of various RNA viruses [<xref rid="B73-idr-17-00061" ref-type="bibr">73</xref>,<xref rid="B74-idr-17-00061" ref-type="bibr">74</xref>]. Host-directed approaches include type I and type III interferons (IFNs), which stimulate the innate immune response by binding to their specific receptors and activating the JAK-STAT signaling pathway. This leads to the expression of hundreds of interferon-stimulated genes (ISGs) that induce antiviral states in infected and neighboring cells [<xref rid="B75-idr-17-00061" ref-type="bibr">75</xref>].</p><p>To design broad-spectrum and evolutionarily adaptable treatments for <italic toggle="yes">Enterovirus</italic> species, researchers can focus on targeting highly conserved viral proteins and host factors essential for viral replication. For example, the non-structural protein 2C of <italic toggle="yes">Enterovirus</italic> can be a potential target due to its conserved role in viral replication and assembly [<xref rid="B76-idr-17-00061" ref-type="bibr">76</xref>]. Lethal mutagenesis uses nucleoside analogs to elevate the viral mutation rate, exploiting viral evolution to push the virus into error catastrophe, a state of irrecoverable genetic damage that renders it nonviable [<xref rid="B77-idr-17-00061" ref-type="bibr">77</xref>]. Another strategy involves host-targeted therapies, such as inhibiting PI4KIII&#946;, a cellular enzyme critical for forming enteroviral replication organelles. This approach reduces the risk of resistance, as it targets host machinery rather than viral proteins, which are more prone to mutation. Combination therapies that pair antivirals with innate immune stimulators have shown synergistic effects in inhibiting <italic toggle="yes">Enterovirus</italic> replication. For instance, the combination of gemcitabine with ribavirin has demonstrated synergistic efficacy in reducing replication in cellular models of EV-A71 and CVB3 (EV-B) infections [<xref rid="B78-idr-17-00061" ref-type="bibr">78</xref>]. These last two drugs are also an example of drug repurposing, which involves leveraging existing compounds developed for other diseases. This approach has emerged as an efficient strategy to accelerate antiviral drug development since their safety and pharmacokinetics have already been evaluated [<xref rid="B35-idr-17-00061" ref-type="bibr">35</xref>]. Overall, these strategies combined with evolutionary insights and host&#8211;virus interaction studies provide a robust framework for developing adaptable, broad-spectrum <italic toggle="yes">Enterovirus</italic> treatments.</p></sec></sec><sec id="sec6-idr-17-00061"><title>6. Emerging Antiviral Candidates for RV-D68 and RVs</title><p>Antiviral compounds aim to disrupt virus replication and spread. They typically target either viral proteins or essential host factors exploited by the virus (<xref rid="idr-17-00061-f005" ref-type="fig">Figure 5</xref>). These compounds are classified based on their target proteins, as shown in <xref rid="idr-17-00061-t001" ref-type="table">Table 1</xref>.</p><sec id="sec6dot1-idr-17-00061"><title>6.1. Capsid Binders</title><p>Capsid binder molecules target the viral capsid of <italic toggle="yes">Enterovirus</italic> to disrupt viral entry and uncoating. They induce rigidity in the capsid by occupying the hydrophobic pocket and altering its pocket factor, enhancing its stability. This prevents conformational changes in the capsid protein, inhibits receptor binding, and blocks viral protein interactions with the host, ultimately preventing the release of the viral genome into the host cell.</p><sec id="sec6dot1dot1-idr-17-00061"><title>6.1.1. Pleconaril</title><p>Pleconaril targets viral VP1 protein and prevents virus entry into host cells. It was originally developed for the treatment of EV and RV respiratory infections and has broad activity against these viruses, including EV-D68 in vitro [<xref rid="B34-idr-17-00061" ref-type="bibr">34</xref>,<xref rid="B88-idr-17-00061" ref-type="bibr">88</xref>,<xref rid="B123-idr-17-00061" ref-type="bibr">123</xref>,<xref rid="B124-idr-17-00061" ref-type="bibr">124</xref>]. In clinical trials for the treatment of upper respiratory tract infection caused by RV, patients who received pleconaril experienced an early and sustained reduction in symptom severity, as well as a one-day decrease in disease duration [<xref rid="B80-idr-17-00061" ref-type="bibr">80</xref>]. Despite these positive antiviral results, pleconaril has not been approved by the Food and Drug Administrations (FDA) due to safety profile concerns [<xref rid="B81-idr-17-00061" ref-type="bibr">81</xref>,<xref rid="B125-idr-17-00061" ref-type="bibr">125</xref>]. Pleconaril induces cytochrome P-450 3A enzymes, which can interact with other medications. Notably, the antiviral reduces the effectiveness of oral contraceptives by decreasing plasma levels of ethinyl estradiol, which the P-450 3A enzymes metabolize [<xref rid="B80-idr-17-00061" ref-type="bibr">80</xref>]. The combination of pleconaril and oral contraceptives is also associated with menstrual irregularities, including breakthrough bleeding and spotting.</p></sec><sec id="sec6dot1dot2-idr-17-00061"><title>6.1.2. Pirodavir and Vapendavir</title><p>Pirodavir is a capsid-binding substituted phenoxy-pyridazinamine with potent in vitro activity against most RV serotypes. This compound has demonstrated significant antiviral effects in controlled trials assessing the efficacy of intranasal pirodavir in experimentally induced RV infection of susceptible volunteers. However, it was associated with higher rates of nasal dryness, blood in mucus, or unpleasant taste on several study days [<xref rid="B83-idr-17-00061" ref-type="bibr">83</xref>]. Vapendavir, a pirodavir derivative, previously referred to as BTA-798, significantly reduces asthma exacerbations caused by RVs [<xref rid="B89-idr-17-00061" ref-type="bibr">89</xref>]. However, pirodavir and vapendavir did not show antiviral effectiveness against EV-D68 in vitro and in vivo in both respiratory and neurological infection models using AG129 mice [<xref rid="B34-idr-17-00061" ref-type="bibr">34</xref>,<xref rid="B100-idr-17-00061" ref-type="bibr">100</xref>,<xref rid="B109-idr-17-00061" ref-type="bibr">109</xref>]. Although both drugs remain experimental, results from a phase II clinical trial of vapendavir are expected in summer 2025 [<xref rid="B83-idr-17-00061" ref-type="bibr">83</xref>,<xref rid="B89-idr-17-00061" ref-type="bibr">89</xref>,<xref rid="B90-idr-17-00061" ref-type="bibr">90</xref>].</p></sec><sec id="sec6dot1dot3-idr-17-00061"><title>6.1.3. Pocapavir</title><p>Pocapavir (V-073), an investigational capsid-binding antiviral showed significant activity against poliovirus in preclinical studies. However, in vitro testing against EV-D68 revealed a lack of effectiveness [<xref rid="B100-idr-17-00061" ref-type="bibr">100</xref>]. Although one study suggested potential anti-RV activity, supporting data remain limited [<xref rid="B86-idr-17-00061" ref-type="bibr">86</xref>]. Some cases do report clinical improvement when used for treatment of severe neonatal enteroviral sepsis and CVB3-induced myocarditis [<xref rid="B85-idr-17-00061" ref-type="bibr">85</xref>,<xref rid="B126-idr-17-00061" ref-type="bibr">126</xref>,<xref rid="B127-idr-17-00061" ref-type="bibr">127</xref>]. It is also available for emergency treatment of severe EV-B infections [<xref rid="B84-idr-17-00061" ref-type="bibr">84</xref>]. More research is needed to assess its efficacy against RV and EV-D68.</p></sec><sec id="sec6dot1dot4-idr-17-00061"><title>6.1.4. R856932</title><p>In 2019, the tetrazole-based compound R856932 was identified as a potent antiviral agent against EV-D68 in vitro. It demonstrated high efficacy against various contemporary EV-D68 strains in the rhabdomyosarcoma (RD) cells model [<xref rid="B88-idr-17-00061" ref-type="bibr">88</xref>].</p></sec><sec id="sec6dot1dot5-idr-17-00061"><title>6.1.5. Quinoline Derivative Compound 19</title><p>Compound 19, a quinoline derivative still in the preclinical stage, has shown significant EV-D68 antiviral activity. This compound exhibited broad-spectrum antiviral effects in vitro, with EC50 values ranging from 0.05 to 0.10 &#956;M against various clinical EV-D68 strains as well as the prototype strain in RD cell lines. Its antiviral activity is believed to result from the 1,2,4-oxadiazole modification, which enhances binding to the hydrophobic pocket of the VP1 protein. Additionally, it showed good pharmacokinetic properties, including acceptable bioavailability in rat models [<xref rid="B87-idr-17-00061" ref-type="bibr">87</xref>].</p></sec></sec><sec id="sec6dot2-idr-17-00061"><title>6.2. Viral Replication Protein Inhibitors</title><p>Viral replication protein inhibitors disrupt key processes such as viral RNA synthesis, protein cleavage, and genome assembly, thereby preventing the production of infectious viral particles [<xref rid="B128-idr-17-00061" ref-type="bibr">128</xref>].</p><sec id="sec6dot2dot1-idr-17-00061"><title>6.2.1. Telaprevir&#8212;2A Protease Inhibitor</title><p>Telaprevir is an antiviral originally developed to treat Hepatitis C virus (HCV). It was found to inhibit the 2A protease of EV-D68 in cell culture [<xref rid="B102-idr-17-00061" ref-type="bibr">102</xref>]. However, telaprevir in combination treatment carries a box warning for serious skin reactions [<xref rid="B129-idr-17-00061" ref-type="bibr">129</xref>]. Telaprevir was removed from the market as an HCV treatment following the introduction of newer HCV NS3/NS4A protease inhibitors. These newer inhibitors have also demonstrated antiviral activity against multiple viruses, including EV-A71, suggesting potential broader applications of this drug class beyond HCV treatment [<xref rid="B130-idr-17-00061" ref-type="bibr">130</xref>].</p></sec><sec id="sec6dot2dot2-idr-17-00061"><title>6.2.2. Guadinine Hydrochloride and Fluoxetine&#8212;2C Protein Inhibitors</title><p>Guadinine hydrochloride and fluoxetine are the most studied 2C protein inhibitors, effectively blocking viral replication [<xref rid="B111-idr-17-00061" ref-type="bibr">111</xref>,<xref rid="B131-idr-17-00061" ref-type="bibr">131</xref>]. Guanidine has been shown to inhibit multiple EV-D68 strains in cell culture and demonstrated in vivo antiviral activity in the EV-D68 respiratory animal model [<xref rid="B96-idr-17-00061" ref-type="bibr">96</xref>]. Despite these compelling results in preclinical studies, it has not yet progressed to clinical trials.</p><p>Fluoxetine (Prozac) is an FDA approved antidepressant that was shown to reduce EV-D68 replication in cell culture [<xref rid="B132-idr-17-00061" ref-type="bibr">132</xref>,<xref rid="B133-idr-17-00061" ref-type="bibr">133</xref>]. Fluoxetine, particularly its S-enantiomer, binds to an allosteric hydrophobic pocket in protein 2C, stabilizing its hexameric form and inhibiting ATPase activity [<xref rid="B94-idr-17-00061" ref-type="bibr">94</xref>]. It demonstrated potential antiviral effects against EV-D68 in vitro, but it was ineffective against RV [<xref rid="B94-idr-17-00061" ref-type="bibr">94</xref>]. Additionally, it showed no antiviral efficacy in EV-D68 infection mouse models [<xref rid="B134-idr-17-00061" ref-type="bibr">134</xref>]. However, in one case involving an immunocompromised pediatric patient with chronic enteroviral encephalitis, fluoxetine treatment led to stabilization and improvement [<xref rid="B135-idr-17-00061" ref-type="bibr">135</xref>]. In a retrospective multicenter cohort study, fluoxetine was relatively well-tolerated, but it did not show a positive efficacy signal for improving long-term outcomes in patients with AFM [<xref rid="B95-idr-17-00061" ref-type="bibr">95</xref>].</p></sec><sec id="sec6dot2dot3-idr-17-00061"><title>6.2.3. Rupintrivir and V-7404&#8212;3C Protease Inhibitors</title><p>Rupintrivir (AG7088), a peptide-mimetic inhibitor targeting the viral 3C protease, has shown potent antiviral activity against all <italic toggle="yes">Enterovirus</italic> species, including various human RV genotypes [<xref rid="B136-idr-17-00061" ref-type="bibr">136</xref>]. In vitro studies also confirm its activity against clinical isolates from the three major EV-D68 clusters [<xref rid="B98-idr-17-00061" ref-type="bibr">98</xref>,<xref rid="B109-idr-17-00061" ref-type="bibr">109</xref>]. However, rupintrivir showed no significant efficacy compared to controls in EV-D68 respiratory and neurological mouse infection models [<xref rid="B96-idr-17-00061" ref-type="bibr">96</xref>]. It has not advanced to later-stage clinical trials and remains unapproved.</p><p>A similar analog, V-7404, was developed with improved oral bioavailability and demonstrated potent activity against EV-D68 isolates [<xref rid="B100-idr-17-00061" ref-type="bibr">100</xref>]. It has advanced to clinical trials as a potential treatment for serious EV infections [<xref rid="B104-idr-17-00061" ref-type="bibr">104</xref>].</p></sec><sec id="sec6dot2dot4-idr-17-00061"><title>6.2.4. Azvudine&#8212;3D Polymerase Inhibitor</title><p>Cytidine analog 2&#8242;-deoxy-2&#8242;-&#946;-fluoro-4&#8242;-azidocytidine, also known as azvudine or FNC, exhibits broad-spectrum antiviral activity against various genotypes, including EV-D68, in neonatal mouse model [<xref rid="B137-idr-17-00061" ref-type="bibr">137</xref>]. EV-D68&#8242;s RNA-dependent RNA polymerase (3Dpol) plays a crucial role in viral genome replication within the replication organelles, and antivirals targeting 3Dpol may act by inhibiting transcript polymerization or inducing lethal mutagenesis [<xref rid="B34-idr-17-00061" ref-type="bibr">34</xref>]. Originally developed as an HIV treatment, azvudine was approved by the Chinese authorities in 2022 for use in treating mild to moderate COVID-19 cases [<xref rid="B91-idr-17-00061" ref-type="bibr">91</xref>]. There are no existing data on its efficacy against RVs.</p></sec><sec id="sec6dot2dot5-idr-17-00061"><title>6.2.5. Ribavirin&#8212;Guanosine Nucleoside Analog</title><p>Ribavirin, a synthetic guanosine nucleoside analog, is an older antiviral medication used for treating chronic Hepatitis C, primarily in combination with interferon-based therapies, and other viruses [<xref rid="B138-idr-17-00061" ref-type="bibr">138</xref>,<xref rid="B139-idr-17-00061" ref-type="bibr">139</xref>]. It is also prescribed for various viral hemorrhagic fevers [<xref rid="B99-idr-17-00061" ref-type="bibr">99</xref>]. It interferes with viral RNA synthesis and mRNA capping, primarily through its active metabolite, ribavirin triphosphate (RTP). RTP inhibits viral RNA-dependent RNA polymerase by binding to the enzyme&#8217;s nucleotide binding site, leading to misincorporation of nucleotides and premature termination of viral RNA synthesis. This results in the production of defective virions and an error catastrophe due to increased mutagenesis [<xref rid="B140-idr-17-00061" ref-type="bibr">140</xref>]. Additionally, ribavirin depletes intracellular GTP levels by inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH), further disrupting viral replication [<xref rid="B141-idr-17-00061" ref-type="bibr">141</xref>]. Ribavirin&#8217;s efficacy varies across RV serotypes in in vitro studies [<xref rid="B98-idr-17-00061" ref-type="bibr">98</xref>]. In addition, its clinical utility is limited by inconsistent in vivo results, often due to bioavailability challenges and safety profile (anemia and potential teratogenicity). When combined with pegylated interferon &#945;2a, its antiviral effect improves, as evidenced by accelerated RV RNA clearance in patients with hypogammaglobulinemia [<xref rid="B142-idr-17-00061" ref-type="bibr">142</xref>]. Its mechanism in RV infection aligns with its broader antiviral properties, including RNA synthesis inhibition and immunomodulation, which shifts the host immune response toward a Th1 phenotype, promoting antiviral immunity [<xref rid="B139-idr-17-00061" ref-type="bibr">139</xref>].</p></sec><sec id="sec6dot2dot6-idr-17-00061"><title>6.2.6. Molnupiravir and EIDD-1931</title><p>This ribonucleoside analog works by inducing lethal mutagenesis during viral RNA replication, thereby disrupting the replication process of RNA viruses. A recent investigation has examined the potential of Beta-D-N4-hydroxycytidine (Emory Institute for Drug Development, EIDD-1931), the active form of molnupiravir, to inhibit <italic toggle="yes">Enterovirus</italic> genotypes, including EV-D68 [<xref rid="B92-idr-17-00061" ref-type="bibr">92</xref>]. Molnupiravir has also demonstrated its broad-spectrum antiviral activity against numerous RNA viruses in animal models [<xref rid="B143-idr-17-00061" ref-type="bibr">143</xref>]. Molnupiravir, the prodrug of EIDD-1931, has received emergency use authorization by FDA for treating SARS-CoV-2 infections and has been approved in several countries [<xref rid="B144-idr-17-00061" ref-type="bibr">144</xref>]. Further studies are necessary to confirm its safety and efficacy specifically for EV-D68 infections in vivo.</p></sec></sec><sec id="sec6dot3-idr-17-00061"><title>6.3. Host Factors Antiviral</title><p>Antiviral strategies targeting host proteins focus on disrupting the interactions between viruses and the cellular machinery they hijack for replication. Unlike direct-acting antivirals that target viral proteins, host-targeted antivirals aim to inhibit key host factors essential for the viral life cycle, such as enzymes, receptors, or signaling pathways. This approach offers a broader spectrum of activity and reduces the likelihood of viral resistance, as host proteins are less prone to mutation.</p><sec id="sec6dot3dot1-idr-17-00061"><title>6.3.1. SAMHDI</title><p>SAMHD1 (Sterile alpha motif and histidine-aspartic acid domain-containing protein 1) is a protein characterized by an N-terminal nuclear localization signal (NLS), a sterile alpha motif (SAM) domain involved in protein interactions, and a catalytic histidine-aspartic acid (HD) domain responsible for its enzymatic activities [<xref rid="B145-idr-17-00061" ref-type="bibr">145</xref>]. Highly expressed in myeloid cells, including dendritic cells, macrophages, and monocytes, SAMHD1 restricts viral infections by depleting cellular deoxynucleoside triphosphates (dNTPs), thereby inhibiting reverse transcription in retroviruses like HIV-1 [<xref rid="B146-idr-17-00061" ref-type="bibr">146</xref>]. A recent study revealed SAMHD1&#8217;s broader antiviral capabilities by inhibiting EVs such as EV-A71 and EV-D68 in vitro through mechanisms independent of its canonical dNTPase or RNase activities [<xref rid="B118-idr-17-00061" ref-type="bibr">118</xref>]. Instead, SAMHD1 disrupts viral assembly by competitively binding to the VP1 capsid protein at the same domain where VP2 would normally attach [<xref rid="B118-idr-17-00061" ref-type="bibr">118</xref>].</p></sec><sec id="sec6dot3dot2-idr-17-00061"><title>6.3.2. Enviroxime and Vemurafenib&#8212;Pi4kiii&#946; Inhibitor</title><p><italic toggle="yes">Enterovirus</italic> genome replication occurs in replication organelles, and host proteins associated with these organelles have been identified as potential antiviral drug targets. Enviroxime inhibits the enzymatic activity of PI4KIII&#946; and has been shown to effectively inhibit several strains of EV-D68 [<xref rid="B109-idr-17-00061" ref-type="bibr">109</xref>,<xref rid="B111-idr-17-00061" ref-type="bibr">111</xref>,<xref rid="B147-idr-17-00061" ref-type="bibr">147</xref>]. PI4KIII&#946; catalyzes the synthesis of phosphatidylinositol 4-phosphate (PI4P) from phosphatidylinositol (PI), playing a central role in membrane trafficking, Golgi complex integrity, and organelle identity [<xref rid="B148-idr-17-00061" ref-type="bibr">148</xref>]. Enviroxime advanced to clinical trials for treating the common cold caused by human rhinovirus but was discontinued in Phase II due to toxicity concerns [<xref rid="B149-idr-17-00061" ref-type="bibr">149</xref>].</p><p>Vemurafenib, an FDA-approved kinase inhibitor developed for the treatment of non-rescuable melanoma, has been repurposed to inhibit PI4KIII&#946;, effectively blocking viral replication across EV-A, B, and C, as well as RVs [<xref rid="B119-idr-17-00061" ref-type="bibr">119</xref>].</p><p>CUR-N399, KRP-A218, and GSK3923868 have shown positive results in phase I trials for their antiviral potential against RV, further supporting the therapeutic relevance of targeting PI4KIII&#946; in enterovirus and other viral infections [<xref rid="B106-idr-17-00061" ref-type="bibr">106</xref>,<xref rid="B112-idr-17-00061" ref-type="bibr">112</xref>,<xref rid="B113-idr-17-00061" ref-type="bibr">113</xref>,<xref rid="B114-idr-17-00061" ref-type="bibr">114</xref>,<xref rid="B117-idr-17-00061" ref-type="bibr">117</xref>].</p></sec><sec id="sec6dot3dot3-idr-17-00061"><title>6.3.3. CRT0066101, CRT0066051 and XX-050&#8212;Protein Kinase D Inhibitor</title><p>Protein Kinase D (PKD) is a serine/threonine kinase that regulates Golgi membrane dynamics and vesicular trafficking-processes that are extensively exploited during viral replication. PKD has been identified as a host factor required for the replication of several picornaviruses, including human rhinovirus [<xref rid="B105-idr-17-00061" ref-type="bibr">105</xref>]. Interestingly, addition of PKD inhibitors, such as CRT0066101, CRT0066051 and XX-050 in infected HeLa cells led to a significant, concentration-dependent reduction in viral genome replication, protein expression, and infectious titers [<xref rid="B105-idr-17-00061" ref-type="bibr">105</xref>]. The antiviral mechanism is thought to disrupt early post-entry steps in replication, rather than viral entry or interferon signaling [<xref rid="B105-idr-17-00061" ref-type="bibr">105</xref>].</p></sec><sec id="sec6dot3dot4-idr-17-00061"><title>6.3.4. Itraconazole&#8212;OSBP Inhibitor</title><p>Itraconazole has shown efficacy as an antiviral agent against <italic toggle="yes">Enterovirus</italic>, including poliovirus, coxsackievirus, EV-A71, and RVs. Its antiviral activity is attributed to several mechanisms, primarily involving the inhibition of OSBP and OSBP-related protein 4 (ORP4), which disrupts cholesterol trafficking essential for viral replication [<xref rid="B116-idr-17-00061" ref-type="bibr">116</xref>]. In vivo experiments have shown that itraconazole reduces viral replication in mice and decreases inflammation in the respiratory tract, highlighting its potential as both a therapeutic and prophylactic agent against <italic toggle="yes">Enterovirus</italic> infections [<xref rid="B115-idr-17-00061" ref-type="bibr">115</xref>].</p></sec><sec id="sec6dot3dot5-idr-17-00061"><title>6.3.5. DAS181&#8212;Inhibitors Targeting the Cell Surface Sialic Acid Receptors</title><p>Sialic acid is a nine-carbon sugar molecule that plays a vital role in cell surface interactions, often found attached to glycoproteins and glycolipids. The way sialic acid connects to other sugars is described by its glycosidic linkage, which is denoted using a specific nomenclature. For example, an &#945;2,6 linkage refers to the bond formed between the C2 carbon of sialic acid and the C6 carbon of the adjacent sugar, such as galactose or N-acetylgalactosamine. This linkage is one of several possible configurations, including &#945;2,3 (C2 to C3) and &#945;2,8 (C2 to C8). The type of linkage determines how sialic acid is presented on cell surfaces, influencing its biological functions. For instance, EV-D68 specifically binds to &#945;2,6-linked sialic acids, enabling viral attachment and entry into host cells [<xref rid="B150-idr-17-00061" ref-type="bibr">150</xref>].</p><p>DAS181, a sialidase enzyme that cleaves sialic acid, exhibited potency in inhibiting the replication of both historical and contemporary EV-D68 strains in RDcells. In vitro studies showed that it significantly inhibited contemporary EV-D68 strains (USA-MO/18947, USA-MO/18949, and USA-MO/18956) as well as the prototype strain (Fermon). Additionally, DAS181 demonstrated strong antiviral activity against EV-B, EV-C, EV-D, and rhinovirus A and B strains [<xref rid="B35-idr-17-00061" ref-type="bibr">35</xref>,<xref rid="B100-idr-17-00061" ref-type="bibr">100</xref>]. However, recent data suggest that its effectiveness against EV-D68 may vary by strain and cell type, indicating that its antiviral activity in RD cells is cell-type dependent [<xref rid="B34-idr-17-00061" ref-type="bibr">34</xref>]. It has also demonstrated high efficacy against pandemic H1N1, avian influenza, and drug-resistant influenza strains [<xref rid="B108-idr-17-00061" ref-type="bibr">108</xref>]. DAS181 has received fast track and breakthrough therapy designations by the FDA for the treatment of severe lower respiratory tract parainfluenza virus infection in immunocompromised patients [<xref rid="B107-idr-17-00061" ref-type="bibr">107</xref>].</p></sec></sec><sec id="sec6dot4-idr-17-00061"><title>6.4. Antibodies</title><p>Recent studies have identified monoclonal antibodies (mAbs) isolated from individuals previously infected with EV-D68 that exhibit broad recognition of diverse antigenic variants [<xref rid="B121-idr-17-00061" ref-type="bibr">121</xref>]. These cross-neutralizing mAbs are now being explored as therapeutic interventions for Enterovirus infections, with the goal of administering them to patients to block viral entry, neutralize circulating virions, or enhance immune clearance. This approach takes advantage of the immune system&#8217;s ability to generate potent, strain-transcending antibodies, offering a strategy to bypass the challenges posed by rapid viral evolution and antigenic diversity [<xref rid="B121-idr-17-00061" ref-type="bibr">121</xref>].</p><sec id="sec6dot4dot1-idr-17-00061"><title>6.4.1. Human Antibodies</title><p>EV68-228 and EV68-159, two human mAbs with demonstrated neutralizing cross-reactivity in vitro, were tested for antiviral efficacy in mouse models with respiratory or AFM-like neurological conditions. Compared to intravenous immunoglobulin, a therapy made from pooled antibodies from the plasma of healthy donors, both mAbs improved survival and protected mice from disease, whether given before or after infection [<xref rid="B121-idr-17-00061" ref-type="bibr">121</xref>]. EV68-228 is in Phase I since June 2024 to evaluate the safety, pharmacokinetics, and optimal dosage in healthy adult volunteers [<xref rid="B122-idr-17-00061" ref-type="bibr">122</xref>]. EV68-159 is not currently in clinical trials.</p><p>Other studies have demonstrated that monoclonal antibodies targeting human intercellular adhesion molecule-1 (ICAM-1) can effectively inhibit rhinovirus-induced exacerbations of lung inflammation [<xref rid="B66-idr-17-00061" ref-type="bibr">66</xref>,<xref rid="B151-idr-17-00061" ref-type="bibr">151</xref>]. ICAM-1 serves as a primary receptor for the major group of rhinoviruses and is upregulated on airway epithelial and endothelial cells during inflammatory responses, facilitating leukocyte adhesion and transmigration [<xref rid="B152-idr-17-00061" ref-type="bibr">152</xref>]. The findings support the potential of anti-ICAM-1 monoclonal antibodies as promising interventions for managing rhinovirus-triggered exacerbations of airway inflammation [<xref rid="B66-idr-17-00061" ref-type="bibr">66</xref>].</p></sec><sec id="sec6dot4dot2-idr-17-00061"><title>6.4.2. Non-Human Antibodies</title><p>Several studies have shown that sera derived from animal models, whether from live virus infections, inactivated virus formulated with alum, or virus-like particles (VLPs), are capable of neutralizing both homologous and heterologous EV-D68 strains in vitro [<xref rid="B153-idr-17-00061" ref-type="bibr">153</xref>,<xref rid="B154-idr-17-00061" ref-type="bibr">154</xref>]. When passively transferred to animals, these sera protected against symptoms and death resulting from infection with the respective strain [<xref rid="B155-idr-17-00061" ref-type="bibr">155</xref>,<xref rid="B156-idr-17-00061" ref-type="bibr">156</xref>,<xref rid="B157-idr-17-00061" ref-type="bibr">157</xref>].</p><p>A study reported the isolation of the VP1-specific A6-1 mAb from an EV-D68-infected rhesus macaque, demonstrating its ability to neutralize the virus. At low concentrations, these mAbs effectively neutralized EV-D68 Kunming and Fermon strains in vitro [<xref rid="B158-idr-17-00061" ref-type="bibr">158</xref>]. In intranasally infected suckling mice, they provided cross-species protection, aiding in viral clearance and preventing hemorrhage and inflammatory cell aggregation in the lungs and brain. These findings suggest that the A6-1 mAb inhibits EV-D68 intranasal infections and mitigates pathological effects in infected mice [<xref rid="B120-idr-17-00061" ref-type="bibr">120</xref>].</p><p>An experimental approach involved sequentially injecting two female BALB/c mice with DNA plasmids encoding capsid proteins and two proteases from various RV-A types, followed by a final boost with the whole virus. This method generated hybridomas expressing mAbs, three of which displayed cross-reactivity against multiple RV-A strains [<xref rid="B159-idr-17-00061" ref-type="bibr">159</xref>]. While RV-A15-specific mAbs exhibited neutralizing activity against RV-A15, the cross-reactive mAbs did not. However, one cross-reactive mAb demonstrated significant antibody-dependent cellular phagocytosis (ADCP) activity. These findings suggest that this approach can produce VP1-specific, cross-reactive antibodies, particularly those with ADCP activity, which may contribute to protection against RV infections. To our knowledge, there are no non-human mAbs currently in clinical trials.</p></sec></sec><sec id="sec6dot5-idr-17-00061"><title>6.5. Vaccines</title><p>In addition to antiviral treatments, vaccines are a critical area of focus for preventing complications associated with enteroviral infections. The success of the poliovirus vaccine illustrates the significant impact of vaccination against these viruses. Since its introduction in the 1950s, global immunization efforts have substantially reduced polio incidence, bringing the disease close to eradication [<xref rid="B160-idr-17-00061" ref-type="bibr">160</xref>]. While no vaccine is currently approved for EV-D68 or RV, a novel bivalent vaccine targeting EV-A71 and EV-D68 has been developed using formalin-inactivated viruses and polysaccharides from the fungi <italic toggle="yes">Ganoderma lucidum</italic> as an adjuvant. This vaccine demonstrated strong mucosal and systemic immune responses in mice, offering protection against lethal challenges [<xref rid="B161-idr-17-00061" ref-type="bibr">161</xref>]. The vaccine remains at the preclinical stage, focusing on animal models to evaluate efficacy and safety. In addition, antibodies generated against the poliovirus vaccine have demonstrated some cross-reactivity with other <italic toggle="yes">Enterovirus</italic> species, including EV-D68 and EV-A71. This cross-protection remains limited and not universal due to the extensive genetic diversity and numerous serotypes of the genus [<xref rid="B50-idr-17-00061" ref-type="bibr">50</xref>,<xref rid="B162-idr-17-00061" ref-type="bibr">162</xref>]. Preclinical studies report that several experimental RV vaccines induce strong, cross-reactive cellular and humoral immune responses in mice enhancing virus clearance, including the induction of broadly neutralizing antibodies against multiple RV serotypes in rhesus macaques [<xref rid="B67-idr-17-00061" ref-type="bibr">67</xref>,<xref rid="B163-idr-17-00061" ref-type="bibr">163</xref>]. For RV, APL-10456, a prophylactic RV vaccine developed by Apollo Therapeutics Ltd. (patent GB202202738D0), is undergoing IND-enabling to prevent exacerbation of major chronic lung conditions [<xref rid="B164-idr-17-00061" ref-type="bibr">164</xref>,<xref rid="B165-idr-17-00061" ref-type="bibr">165</xref>]. Continued innovation in vaccine design and adjuvant selection will be essential to overcome these challenges and achieve broad, durable protection.</p></sec></sec><sec sec-type="conclusions" id="sec7-idr-17-00061"><title>7. Conclusions</title><p>The recent pandemic has revealed the staggering economic cost of insufficient preparedness for emerging viral threats and the critical importance of proactive research in virology [<xref rid="B166-idr-17-00061" ref-type="bibr">166</xref>]. EVs and RVs continue to evolve, posing a risk as demonstrated by the EV-D68 outbreak in 2014. While no treatment is currently available, many compounds have shown potential. These compounds target a broad range of viral processes, with a particular focus on viral attachment, RO formation, and RNA replication. However, other stages of the viral life cycle have not been explored as potential therapeutic targets. For instance, inhibitors targeting viral release have been successfully developed against HIV, an approach not widely investigated for <italic toggle="yes">Enterovirus</italic> [<xref rid="B167-idr-17-00061" ref-type="bibr">167</xref>,<xref rid="B168-idr-17-00061" ref-type="bibr">168</xref>]. Given these gaps, repurposing existing antivirals developed for other viruses presents an opportunity to explore novel mechanisms of inhibition. Building on the existing cellular, tissue, and animal models that provide a strong foundation for antiviral research, we can anticipate significant advancements in the development of novel therapeutics. By prioritizing investment in these areas today, we can ensure that we are better equipped to address the significant health burden caused by EV-D68, RVs, ultimately improving public health and reducing societal disruption.</p></sec></body><back><ack><title>Acknowledgments</title><p>This paper is part of the Special Issue entitled &#8220;Prevention, Diagnosis, and Treatment of Infectious Diseases&#8221;, dedicated to the 50th anniversary of the research center in infectious diseases, founded by Michel G. Bergeron, at the CHU de Qu&#233;bec-Universit&#233; Laval&#8217;s Research Center. We would like to extend our sincere gratitude to Michel G. Bergeron for his invaluable contributions and for creating such an exceptional research environment.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, V.L.R., M.T., S.I., S.T. and M.B.; methodology, writing&#8212;original draft preparation, visualization, V.L.R., M.T. and S.T.; validation, writing&#8212;review and editing, H.R., Y.G.S., M.C.M., S.I., S.T. and M.B.; supervision, S.I., S.T. and M.B.; project administration, M.B.; funding acquisition, S.I. and M.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were generated or analyzed.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-idr-17-00061"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Khamrin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maneekarn</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kumthip</surname><given-names>K.</given-names></name></person-group><article-title>Epidemiology of Enterovirus Genotypes in Association with Human Diseas Es</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>1165</elocation-id><pub-id pub-id-type="doi">10.3390/v16071165</pub-id><pub-id pub-id-type="pmid">39066327</pub-id><pub-id pub-id-type="pmcid">PMC11281466</pub-id></element-citation></ref><ref id="B2-idr-17-00061"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Messacar</surname><given-names>K.</given-names></name></person-group><article-title>Overview of Enterovirus Infections</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.merckmanuals.com/en-ca/professional/infectious-diseases/enteroviruses/overview-of-enterovirus-infections" ext-link-type="uri">https://www.merckmanuals.com/en-ca/professional/infectious-diseases/enteroviruses/overview-of-enterovirus-infections</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-25">(accessed on 25 March 2025)</date-in-citation></element-citation></ref><ref id="B3-idr-17-00061"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halabi</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Stockwell</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Alba</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saiman</surname><given-names>L.</given-names></name></person-group><article-title>Mobile Surveillance for Acute Respiratory Infection/Influenza-like Illness in the Community (MoSAIC) Study Team Clinical and Socioeconomic Burden of Rhinoviruses/Enteroviruses in the Community</article-title><source>Influenza Other Respir. Viruses</source><year>2022</year><volume>16</volume><fpage>891</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1111/irv.12989</pub-id><pub-id pub-id-type="pmid">35485187</pub-id><pub-id pub-id-type="pmcid">PMC9343330</pub-id></element-citation></ref><ref id="B4-idr-17-00061"><label>4.</label><element-citation publication-type="webpage"><article-title>ICTV Report Consortium Picornaviridae</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ictv.global/report/chapter/picornaviridae/picornaviridae/enterovirus" ext-link-type="uri">https://ictv.global/report/chapter/picornaviridae/picornaviridae/enterovirus</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-23">(accessed on 23 February 2025)</date-in-citation></element-citation></ref><ref id="B5-idr-17-00061"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mammas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Drysdale</surname><given-names>S.</given-names></name><name name-style="western"><surname>Theodoridou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greenough</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spandidos</surname><given-names>D.</given-names></name></person-group><article-title>Viruses, Vaccinations and RSV: Exploring Terminology in Paediatric Virology</article-title><source>Exp. Ther. Med.</source><year>2020</year><volume>20</volume><fpage>300</fpage><pub-id pub-id-type="doi">10.3892/etm.2020.9430</pub-id><pub-id pub-id-type="pmid">33209144</pub-id><pub-id pub-id-type="pmcid">PMC7668151</pub-id></element-citation></ref><ref id="B6-idr-17-00061"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freeman</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Ciomperlik-Patton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Myerburg</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Konopka-Anstadt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coyne</surname><given-names>C.B.</given-names></name></person-group><article-title>Respiratory and Intestinal Epithelial Cells Exhibit Differential Susceptibility and Innate Immune Responses to Contemporary EV-D68 Isolates</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e66687</fpage><pub-id pub-id-type="doi">10.7554/eLife.66687</pub-id><pub-id pub-id-type="pmid">34196272</pub-id><pub-id pub-id-type="pmcid">PMC8285104</pub-id></element-citation></ref><ref id="B7-idr-17-00061"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dutilh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reist</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bingisser</surname><given-names>R.</given-names></name><name name-style="western"><surname>Egli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heininger</surname><given-names>U.</given-names></name></person-group><article-title>Clinical Presentation of Enterovirus D68 in a Swiss Pediatric Universi Ty Center</article-title><source>Pediatr. Infect. Dis. J.</source><year>2024</year><volume>43</volume><fpage>1135</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000004503</pub-id><pub-id pub-id-type="pmid">39163309</pub-id><pub-id pub-id-type="pmcid">PMC11542972</pub-id></element-citation></ref><ref id="B8-idr-17-00061"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodcroft</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Dyrdak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Andr&#233;s</surname><given-names>C.</given-names></name><name name-style="western"><surname>Egli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reist</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garc&#237;a Mart&#237;nez De Artola</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alcoba Fl&#243;rez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niesters</surname><given-names>H.G.M.</given-names></name><name name-style="western"><surname>Ant&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poelman</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Evolution, Geographic Spreading, and Demographic Distribution of Enter Ovirus D68</article-title><source>PLoS Pathog.</source><year>2020</year><volume>18</volume><elocation-id>e1010515</elocation-id><pub-id pub-id-type="doi">10.1101/2020.01.10.901553</pub-id><pub-id pub-id-type="pmcid">PMC9212145</pub-id><pub-id pub-id-type="pmid">35639811</pub-id></element-citation></ref><ref id="B9-idr-17-00061"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holm-Hansen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Midgley</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>T.K.</given-names></name></person-group><article-title>Global Emergence of Enterovirus D68: A Systematic Review</article-title><source>Lancet Infect. Dis.</source><year>2016</year><volume>16</volume><fpage>e64</fpage><lpage>e75</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00543-5</pub-id><pub-id pub-id-type="pmid">26929196</pub-id></element-citation></ref><ref id="B10-idr-17-00061"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monto</surname><given-names>A.S.</given-names></name></person-group><article-title>Epidemiology of Viral Respiratory Infections</article-title><source>Am. J. Med.</source><year>2002</year><volume>112</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(01)01058-0</pub-id><pub-id pub-id-type="pmid">11955454</pub-id></element-citation></ref><ref id="B11-idr-17-00061"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gern</surname><given-names>J.E.</given-names></name></person-group><article-title>The ABCs of Rhinoviruses, Wheezing, and Asthma</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>7418</fpage><lpage>7426</lpage><pub-id pub-id-type="doi">10.1128/JVI.02290-09</pub-id><pub-id pub-id-type="pmid">20375160</pub-id><pub-id pub-id-type="pmcid">PMC2897627</pub-id></element-citation></ref><ref id="B12-idr-17-00061"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McManus</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Marley</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Christie</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Elborn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Kidney</surname><given-names>J.C.</given-names></name></person-group><article-title>Respiratory Viral Infection in Exacerbations of COPD</article-title><source>Respir. Med.</source><year>2008</year><volume>102</volume><fpage>1575</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2008.06.006</pub-id><pub-id pub-id-type="pmid">18672353</pub-id><pub-id pub-id-type="pmcid">PMC7125807</pub-id></element-citation></ref><ref id="B13-idr-17-00061"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Pattemore</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lampe</surname><given-names>F.</given-names></name><name name-style="western"><surname>Josephs</surname><given-names>L.</given-names></name><name name-style="western"><surname>Symington</surname><given-names>P.</given-names></name><name name-style="western"><surname>O&#8217;Toole</surname><given-names>S.</given-names></name><name name-style="western"><surname>Myint</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Tyrrell</surname><given-names>D.A.J.</given-names></name><etal/></person-group><article-title>Community Study of Role of Viral Infections in Exacerbations of Asthma in 9&#8211;11 Year Old Children</article-title><source>BMJ</source><year>1995</year><volume>310</volume><fpage>1225</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1136/bmj.310.6989.1225</pub-id><pub-id pub-id-type="pmid">7767192</pub-id><pub-id pub-id-type="pmcid">PMC2549614</pub-id></element-citation></ref><ref id="B14-idr-17-00061"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wark</surname><given-names>P.A.B.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Moric</surname><given-names>I.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>P.G.</given-names></name></person-group><article-title>Neutrophil Degranulation and Cell Lysis Is Associated with Clinical Severity in Virus-Induced Asthma</article-title><source>Eur. Respir. J.</source><year>2002</year><volume>19</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1183/09031936.02.00226302</pub-id><pub-id pub-id-type="pmid">11852895</pub-id></element-citation></ref><ref id="B15-idr-17-00061"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grissell</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shafren</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>P.G.</given-names></name></person-group><article-title>Interleukin-10 Gene Expression in Acute Virus-Induced Asthma</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2005</year><volume>172</volume><fpage>433</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1164/rccm.200412-1621OC</pub-id><pub-id pub-id-type="pmid">15894599</pub-id></element-citation></ref><ref id="B16-idr-17-00061"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arden</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Nissen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Sloots</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>I.M.</given-names></name></person-group><article-title>Newly Identified Respiratory Viruses in Children with Asthma Exacerbation Not Requiring Admission to Hospital</article-title><source>J. Med. Virol.</source><year>2010</year><volume>82</volume><fpage>1458</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1002/jmv.21819</pub-id><pub-id pub-id-type="pmid">20572080</pub-id></element-citation></ref><ref id="B17-idr-17-00061"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Message</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Kebadze</surname><given-names>T.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kon</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>S.L.</given-names></name></person-group><article-title>An Experimental Model of Rhinovirus Induced Chronic Obstructive Pulmonary Disease Exacerbations: A Pilot Study</article-title><source>Respir. Res.</source><year>2006</year><volume>7</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-7-116</pub-id><pub-id pub-id-type="pmid">16956406</pub-id><pub-id pub-id-type="pmcid">PMC1578567</pub-id></element-citation></ref><ref id="B18-idr-17-00061"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Message</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Gielen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Contoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kebadze</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aniscenko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Laza-Stanca</surname><given-names>V.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Slater</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive Pulmonary Disease Exacerbation</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2011</year><volume>183</volume><fpage>734</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1164/rccm.201006-0833OC</pub-id><pub-id pub-id-type="pmid">20889904</pub-id><pub-id pub-id-type="pmcid">PMC3081284</pub-id></element-citation></ref><ref id="B19-idr-17-00061"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asner</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Petrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Mertz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Smieja</surname><given-names>M.</given-names></name></person-group><article-title>Clinical Severity of Rhinovirus/Enterovirus Compared to Other Respiratory Viruses in Children</article-title><source>Influenza Other Respir. Viruses</source><year>2014</year><volume>8</volume><fpage>436</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1111/irv.12255</pub-id><pub-id pub-id-type="pmid">24801963</pub-id><pub-id pub-id-type="pmcid">PMC4181803</pub-id></element-citation></ref><ref id="B20-idr-17-00061"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Sarmiento</surname><given-names>J.</given-names></name><name name-style="western"><surname>Corrales</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Obando</surname><given-names>E.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bastidas Goyes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrera Lopez</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Bernal Ortiz</surname><given-names>N.</given-names></name></person-group><article-title>Factors Associated with Severe Acute Respiratory Infections Due to Rhinovirus/Enterovirus Complex in Children and Their Comparison with Those of Respiratory Syncytial Virus</article-title><source>Arch. Pediatr. Infect. Dis.</source><year>2021</year><volume>10</volume><fpage>e115548</fpage><pub-id pub-id-type="doi">10.5812/pedinfect.115548</pub-id></element-citation></ref><ref id="B21-idr-17-00061"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baggen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thibaut</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Strating</surname><given-names>J.R.P.M.</given-names></name><name name-style="western"><surname>Van Kuppeveld</surname><given-names>F.J.M.</given-names></name></person-group><article-title>The Life Cycle of Non-Polio Enteroviruses and How to Target It</article-title><source>Nat. Rev. Microbiol.</source><year>2018</year><volume>16</volume><fpage>368</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0005-4</pub-id><pub-id pub-id-type="pmid">29626210</pub-id></element-citation></ref><ref id="B22-idr-17-00061"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmonds</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Harvala</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hovi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Oberste</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Palmenberg</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Skern</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Recommendations for the Nomenclature of Enteroviruses and Rhinoviruses</article-title><source>Arch. Virol.</source><year>2020</year><volume>165</volume><fpage>793</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1007/s00705-019-04520-6</pub-id><pub-id pub-id-type="pmid">31980941</pub-id><pub-id pub-id-type="pmcid">PMC7024059</pub-id></element-citation></ref><ref id="B23-idr-17-00061"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thoelen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mo&#235;s</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lemey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mostmans</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wollants</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Vandamme</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Van Ranst</surname><given-names>M.</given-names></name></person-group><article-title>Analysis of the Serotype and Genotype Correlation of VP1 and the 5&#8242; Noncoding Region in an Epidemiological Survey of the Human Enterovirus B Species</article-title><source>J. Clin. Microbiol.</source><year>2004</year><volume>42</volume><fpage>963</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1128/JCM.42.3.963-971.2004</pub-id><pub-id pub-id-type="pmid">15004039</pub-id><pub-id pub-id-type="pmcid">PMC356875</pub-id></element-citation></ref><ref id="B24-idr-17-00061"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filipe</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Guedes</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Zdobnov</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Tapparel</surname><given-names>C.</given-names></name></person-group><article-title>Enterovirus D: A Small but Versatile Species</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><elocation-id>1758</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms9081758</pub-id><pub-id pub-id-type="pmid">34442837</pub-id><pub-id pub-id-type="pmcid">PMC8400195</pub-id></element-citation></ref><ref id="B25-idr-17-00061"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joffret</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Polston</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Razafindratsimandresy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bessaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heraud</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Delpeyroux</surname><given-names>F.</given-names></name></person-group><article-title>Whole Genome Sequencing of Enteroviruses Species A to D by High-Throughput Sequencing: Application for Viral Mixtures</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><elocation-id>2339</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.02339</pub-id><pub-id pub-id-type="pmid">30323802</pub-id><pub-id pub-id-type="pmcid">PMC6172331</pub-id></element-citation></ref><ref id="B26-idr-17-00061"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>F&#252;zik</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moravcov&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalynych</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plevka</surname><given-names>P.</given-names></name></person-group><article-title>Structure of Human Enterovirus 70 and Its Inhibition by Capsid-Binding Compounds</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e0060422</fpage><pub-id pub-id-type="doi">10.1128/jvi.00604-22</pub-id><pub-id pub-id-type="pmid">35939401</pub-id><pub-id pub-id-type="pmcid">PMC9472761</pub-id></element-citation></ref><ref id="B27-idr-17-00061"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plevka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yap</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Cardosa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Rossmann</surname><given-names>M.G.</given-names></name></person-group><article-title>Structure of Human Enterovirus 71 in Complex with a Capsid-Binding Inhibitor</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>5463</fpage><lpage>5467</lpage><pub-id pub-id-type="doi">10.1073/pnas.1222379110</pub-id><pub-id pub-id-type="pmid">23509286</pub-id><pub-id pub-id-type="pmcid">PMC3619292</pub-id></element-citation></ref><ref id="B28-idr-17-00061"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name></person-group><article-title>The Structure, Function, and Mechanisms of Action of Enterovirus Non-Structural Protein 2C</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>615965</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.615965</pub-id><pub-id pub-id-type="pmid">33381104</pub-id><pub-id pub-id-type="pmcid">PMC7767853</pub-id></element-citation></ref><ref id="B29-idr-17-00061"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzgerald</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Semler</surname><given-names>B.L.</given-names></name></person-group><article-title>Bridging IRES Elements in mRNAs to the Eukaryotic Translation Apparatus</article-title><source>Biochim. Biophys. Acta BBA&#8212;Gene Regul. Mech.</source><year>2009</year><volume>1789</volume><fpage>518</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2009.07.004</pub-id><pub-id pub-id-type="pmcid">PMC2783899</pub-id><pub-id pub-id-type="pmid">19631772</pub-id></element-citation></ref><ref id="B30-idr-17-00061"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muslin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mac Kain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bessaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blondel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Delpeyroux</surname><given-names>F.</given-names></name></person-group><article-title>Recombination in Enteroviruses, a Multi-Step Modular Evolutionary Process</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>859</elocation-id><pub-id pub-id-type="doi">10.3390/v11090859</pub-id><pub-id pub-id-type="pmid">31540135</pub-id><pub-id pub-id-type="pmcid">PMC6784155</pub-id></element-citation></ref><ref id="B31-idr-17-00061"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Linden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wolthers</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>van Kuppeveld</surname><given-names>F.J.M.</given-names></name></person-group><article-title>Replication and Inhibitors of Enteroviruses and Parechoviruses</article-title><source>Viruses</source><year>2015</year><volume>7</volume><fpage>4529</fpage><lpage>4562</lpage><pub-id pub-id-type="doi">10.3390/v7082832</pub-id><pub-id pub-id-type="pmid">26266417</pub-id><pub-id pub-id-type="pmcid">PMC4576193</pub-id></element-citation></ref><ref id="B32-idr-17-00061"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchta</surname><given-names>D.</given-names></name><name name-style="western"><surname>F&#252;zik</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hreb&#237;k</surname><given-names>D.</given-names></name><name name-style="western"><surname>Levdansky</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suken&#237;k</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mukhamedova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moravcov&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>V&#225;cha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Plevka</surname><given-names>P.</given-names></name></person-group><article-title>Enterovirus Particles Expel Capsid Pentamers to Enable Genome Release</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>1138</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09132-x</pub-id><pub-id pub-id-type="pmid">30850609</pub-id><pub-id pub-id-type="pmcid">PMC6408523</pub-id></element-citation></ref><ref id="B33-idr-17-00061"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melia</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Peddie</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>A.W.M.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Collinson</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Van Der Schaar</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Van Kuppeveld</surname><given-names>F.J.M.</given-names></name><name name-style="western"><surname>B&#225;rcena</surname><given-names>M.</given-names></name></person-group><article-title>Origins of Enterovirus Replication Organelles Established by Whole-Cell Electron Microscopy</article-title><source>mBio</source><year>2019</year><volume>10</volume><fpage>e00951-19</fpage><pub-id pub-id-type="doi">10.1128/mBio.00951-19</pub-id><pub-id pub-id-type="pmid">31186324</pub-id><pub-id pub-id-type="pmcid">PMC6561026</pub-id></element-citation></ref><ref id="B34-idr-17-00061"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Musharrafieh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Enterovirus D68 Antivirals: Past, Present, and Future</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1572</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00120</pub-id><pub-id pub-id-type="pmid">32352280</pub-id><pub-id pub-id-type="pmcid">PMC8055446</pub-id></element-citation></ref><ref id="B35-idr-17-00061"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Balasubramaniam</surname><given-names>V.R.M.T.</given-names></name></person-group><article-title>Emerging Therapeutics in the Fight Against EV-D68: A Review of Current Strategies</article-title><source>Influenza Other Respir. Viruses</source><year>2024</year><volume>18</volume><fpage>e70064</fpage><pub-id pub-id-type="doi">10.1111/irv.70064</pub-id><pub-id pub-id-type="pmid">39702696</pub-id><pub-id pub-id-type="pmcid">PMC11659119</pub-id></element-citation></ref><ref id="B36-idr-17-00061"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suhy</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Giddings</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Kirkegaard</surname><given-names>K.</given-names></name></person-group><article-title>Remodeling the Endoplasmic Reticulum by Poliovirus Infection and by Individual Viral Proteins: An Autophagy-Like Origin for Virus-Induced Vesicles</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>8953</fpage><lpage>8965</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.19.8953-8965.2000</pub-id><pub-id pub-id-type="pmid">10982339</pub-id><pub-id pub-id-type="pmcid">PMC102091</pub-id></element-citation></ref><ref id="B37-idr-17-00061"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Enterovirus Replication Organelles and Inhibitors of Their Formation</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>1817</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.01817</pub-id><pub-id pub-id-type="pmid">32973693</pub-id><pub-id pub-id-type="pmcid">PMC7468505</pub-id></element-citation></ref><ref id="B38-idr-17-00061"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galitska</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jassey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>W.T.</given-names></name></person-group><article-title>Enterovirus D68 Capsid Formation and Stability Requires Acidic Compartments</article-title><source>mBio</source><year>2023</year><volume>14</volume><elocation-id>e0214123</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.02141-23</pub-id><pub-id pub-id-type="pmid">37819109</pub-id><pub-id pub-id-type="pmcid">PMC10653823</pub-id></element-citation></ref><ref id="B39-idr-17-00061"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owusu</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Quaye</surname><given-names>O.</given-names></name><name name-style="western"><surname>Passalacqua</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Wobus</surname><given-names>C.E.</given-names></name></person-group><article-title>Egress of Non-Enveloped Enteric RNA Viruses</article-title><source>J. Gen. Virol.</source><year>2021</year><volume>102</volume><fpage>1557</fpage><pub-id pub-id-type="doi">10.1099/jgv.0.001557</pub-id><pub-id pub-id-type="pmcid">PMC8515858</pub-id><pub-id pub-id-type="pmid">33560198</pub-id></element-citation></ref><ref id="B40-idr-17-00061"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salmikangas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Laiho</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kalander</surname><given-names>K.</given-names></name><name name-style="western"><surname>Laajala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honkimaa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shanina</surname><given-names>I.</given-names></name><name name-style="western"><surname>Oikarinen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hy&#246;ty</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marjom&#228;ki</surname><given-names>V.</given-names></name></person-group><article-title>Detection of Viral &#8722;RNA and +RNA Strands in Enterovirus-Infected Cells and Tissues</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>1928</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8121928</pub-id><pub-id pub-id-type="pmid">33291747</pub-id><pub-id pub-id-type="pmcid">PMC7761939</pub-id></element-citation></ref><ref id="B41-idr-17-00061"><label>41.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Haller</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Semler</surname><given-names>B.L.</given-names></name></person-group><article-title>Translation and Host Cell Shutoff</article-title><source>Human Enterovirus Infections</source><person-group person-group-type="editor"><name name-style="western"><surname>Rotbart</surname><given-names>H.A.</given-names></name></person-group><publisher-name>ASM Press</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2014</year><fpage>113</fpage><lpage>133</lpage><isbn>978-1-68367-272-2</isbn></element-citation></ref><ref id="B42-idr-17-00061"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.-C.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>K.-F.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.-N.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>S.-R.</given-names></name></person-group><article-title>Development of Antiviral Agents for Enteroviruses</article-title><source>J. Antimicrob. Chemother.</source><year>2008</year><volume>62</volume><fpage>1169</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn424</pub-id><pub-id pub-id-type="pmid">18931391</pub-id></element-citation></ref><ref id="B43-idr-17-00061"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eshaghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duvvuri</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Isabel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Gubbay</surname><given-names>J.B.</given-names></name></person-group><article-title>Global Distribution and Evolutionary History of Enterovirus D68, with Emphasis on the 2014 Outbreak in Ontario, Canada</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><elocation-id>257</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.00257</pub-id><pub-id pub-id-type="pmid">28298902</pub-id><pub-id pub-id-type="pmcid">PMC5331033</pub-id></element-citation></ref><ref id="B44-idr-17-00061"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messacar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abzug</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Dominguez</surname><given-names>S.R.</given-names></name></person-group><article-title>2014 Outbreak of Enterovirus D68 in North America</article-title><source>J. Med. Virol.</source><year>2016</year><volume>88</volume><fpage>739</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1002/jmv.24410</pub-id><pub-id pub-id-type="pmid">26489019</pub-id></element-citation></ref><ref id="B45-idr-17-00061"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benschop</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andr&#233;s</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aranzamendi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armannsd&#243;ttir</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bailly</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Baldanti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Baldvinsd&#243;ttir</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Beard</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Re-Emergence of Enterovirus D68 in Europe after Easing the COVID-19 Lockdown, September 2021</article-title><source>Eurosurveillance</source><year>2021</year><volume>26</volume><fpage>2100998</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.45.2100998</pub-id><pub-id pub-id-type="pmid">34763750</pub-id><pub-id pub-id-type="pmcid">PMC8646978</pub-id></element-citation></ref><ref id="B46-idr-17-00061"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name></person-group><article-title>Enterovirus D68-Associated Severe Pneumonia, China, 2014</article-title><source>Emerg. Infect. Dis.</source><year>2015</year><volume>21</volume><fpage>916</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.3201/eid2105.150036</pub-id><pub-id pub-id-type="pmid">25897574</pub-id><pub-id pub-id-type="pmcid">PMC4412250</pub-id></element-citation></ref><ref id="B47-idr-17-00061"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thongpan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wanlapakorn</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vongpunsawad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Linsuwanon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Theamboonlers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Payungporn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poovorawan</surname><given-names>Y.</given-names></name></person-group><article-title>Prevalence and Phylogenetic Characterization of Enterovirus D68 in Pediatric Patients with Acute Respiratory Tract Infection in Thailand</article-title><source>Jpn. J. Infect. Dis.</source><year>2016</year><volume>69</volume><fpage>426</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.7883/yoken.JJID.2015.352</pub-id><pub-id pub-id-type="pmid">26567839</pub-id></element-citation></ref><ref id="B48-idr-17-00061"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jallow</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mendy</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Diagne</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sagne</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Tall</surname><given-names>F.</given-names></name><name name-style="western"><surname>Diouf</surname><given-names>J.B.N.</given-names></name><name name-style="western"><surname>Ndiaye</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Kiori</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sy</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Real-Time Enterovirus D68 Outbreak Detection through Hospital Surveillance of Severe Acute Respiratory Infection, Senegal, 2023</article-title><source>Emerg. Infect. Dis.</source><year>2024</year><volume>30</volume><fpage>1687</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.3201/eid3008.240410</pub-id><pub-id pub-id-type="pmid">39043450</pub-id><pub-id pub-id-type="pmcid">PMC11286061</pub-id></element-citation></ref><ref id="B49-idr-17-00061"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schuffenecker</surname><given-names>I.</given-names></name><name name-style="western"><surname>Casalegno</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Josset</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armand</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dhondt</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Escuret</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lina</surname><given-names>B.</given-names></name></person-group><article-title>Enterovirus D68 Nosocomial Outbreak in Elderly People, France, 2014</article-title><source>Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.</source><year>2015</year><volume>21</volume><fpage>e61</fpage><lpage>e62</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2015.05.008</pub-id><pub-id pub-id-type="pmid">25986875</pub-id><pub-id pub-id-type="pmcid">PMC7129224</pub-id></element-citation></ref><ref id="B50-idr-17-00061"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Scheuermann</surname><given-names>R.H.</given-names></name></person-group><article-title>Epidemiology and Sequence-Based Evolutionary Analysis of Circulating Non-Polio Enteroviruses</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>1856</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8121856</pub-id><pub-id pub-id-type="pmid">33255654</pub-id><pub-id pub-id-type="pmcid">PMC7759938</pub-id></element-citation></ref><ref id="B51-idr-17-00061"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Winn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moline</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Scobie</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Midgley</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kirking</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Adjemian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hartnett</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Johns</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Increase in Acute Respiratory Illnesses Among Children and Adolescents Associated with Rhinoviruses and Enteroviruses, Including Enterovirus D68&#8212;United States, July-September 2022</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2022</year><volume>71</volume><fpage>1265</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7140e1</pub-id><pub-id pub-id-type="pmid">36201400</pub-id><pub-id pub-id-type="pmcid">PMC9541033</pub-id></element-citation></ref><ref id="B52-idr-17-00061"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunnill</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eshaghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Damodaran</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nagra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gharouni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braukmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Isabel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banh</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Inferring Enterovirus D68 Transmission Dynamics from the Genomic Data of Two 2022 North American Outbreaks</article-title><source>Npj Viruses</source><year>2024</year><volume>2</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1038/s44298-024-00047-z</pub-id><pub-id pub-id-type="pmid">40295704</pub-id><pub-id pub-id-type="pmcid">PMC11721450</pub-id></element-citation></ref><ref id="B53-idr-17-00061"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luong</surname><given-names>Q.X.T.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Ayun</surname><given-names>R.Q.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name></person-group><article-title>Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses</article-title><source>Int. J. Mol. Sci.</source><year>2025</year><volume>26</volume><elocation-id>1481</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26041481</pub-id><pub-id pub-id-type="pmid">40003946</pub-id><pub-id pub-id-type="pmcid">PMC11855616</pub-id></element-citation></ref><ref id="B54-idr-17-00061"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devries</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Bochkov</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Gern</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>D.J.</given-names></name></person-group><article-title>Recent Clinical Isolates of Enterovirus D68 Have Increased Replication and Induce Enhanced Epithelial Immune Response Compared to the Protot Ype Fermon Strain</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1291</elocation-id><pub-id pub-id-type="doi">10.3390/v15061291</pub-id><pub-id pub-id-type="pmid">37376591</pub-id><pub-id pub-id-type="pmcid">PMC10305710</pub-id></element-citation></ref><ref id="B55-idr-17-00061"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Simmonds</surname><given-names>P.</given-names></name><name name-style="western"><surname>Harvala</surname><given-names>H.</given-names></name></person-group><article-title>The Importance of Enterovirus Surveillance in a Post-Polio World</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>e35</fpage><lpage>e40</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30852-5</pub-id><pub-id pub-id-type="pmid">34265258</pub-id></element-citation></ref><ref id="B56-idr-17-00061"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drummond</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Nickerson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Coyne</surname><given-names>C.B.</given-names></name></person-group><article-title>A Three-Dimensional Cell Culture Model To Study Enterovirus Infection of Polarized Intestinal Epithelial Cells</article-title><source>mSphere</source><year>2016</year><volume>1</volume><fpage>e00030-15</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00030-15</pub-id><pub-id pub-id-type="pmid">27303677</pub-id><pub-id pub-id-type="pmcid">PMC4863623</pub-id></element-citation></ref><ref id="B57-idr-17-00061"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basta</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sgro</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Bochkov</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Gern</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Palmenberg</surname><given-names>A.C.</given-names></name></person-group><article-title>Modeling of the Human Rhinovirus C Capsid Suggests Possible Causes for Antiviral Drug Resistance</article-title><source>Virology</source><year>2014</year><volume>448</volume><fpage>82</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.10.004</pub-id><pub-id pub-id-type="pmid">24314639</pub-id><pub-id pub-id-type="pmcid">PMC3878079</pub-id></element-citation></ref><ref id="B58-idr-17-00061"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aguayo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cihlar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Birkus</surname><given-names>G.</given-names></name></person-group><article-title>Multiple Classes of Antiviral Agents Exhibit In Vitro Activity against Human Rhinovirus Type C</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>1546</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1128/AAC.01746-13</pub-id><pub-id pub-id-type="pmid">24366736</pub-id><pub-id pub-id-type="pmcid">PMC3957863</pub-id></element-citation></ref><ref id="B59-idr-17-00061"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Sanden</surname><given-names>S.M.G.</given-names></name><name name-style="western"><surname>Sachs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Koekkoek</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Koen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pajkrt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clevers</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wolthers</surname><given-names>K.C.</given-names></name></person-group><article-title>Enterovirus 71 Infection of Human Airway Organoids Reveals VP1-145 as a Viral Infectivity Determinant</article-title><source>Emerg. Microbes Infect.</source><year>2018</year><volume>7</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.1038/s41426-018-0077-2</pub-id><pub-id pub-id-type="pmid">29743570</pub-id><pub-id pub-id-type="pmcid">PMC5943241</pub-id></element-citation></ref><ref id="B60-idr-17-00061"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sridhar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Depla</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Karelehto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kruiswijk</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vieira De S&#225;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Evers</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Van Kuppeveld</surname><given-names>F.J.M.</given-names></name><etal/></person-group><article-title>Enterovirus D68 Infection in Human Primary Airway and Brain Organoids: No Additional Role for Heparan Sulfate Binding for Neurotropism</article-title><source>Microbiol. Spectr.</source><year>2022</year><volume>10</volume><fpage>e01694-22</fpage><pub-id pub-id-type="doi">10.1128/spectrum.01694-22</pub-id><pub-id pub-id-type="pmid">36154279</pub-id><pub-id pub-id-type="pmcid">PMC9603061</pub-id></element-citation></ref><ref id="B61-idr-17-00061"><label>61.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Xatzipsalti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>N.G.</given-names></name></person-group><article-title>Cellular and Animals Models for Rhinovirus Infection in Asthma</article-title><source>Contributions to Microbiology</source><person-group person-group-type="editor"><name name-style="western"><surname>Sj&#246;bring</surname><given-names>U.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.D.</given-names></name></person-group><publisher-name>KARGER</publisher-name><publisher-loc>Basel, Switzerland</publisher-loc><year>2007</year><fpage>33</fpage><lpage>41</lpage><isbn>978-3-8055-8332-9</isbn><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000107053</pub-id><pub-id pub-id-type="pmid">17684331</pub-id></element-citation></ref><ref id="B62-idr-17-00061"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermillion</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Dearing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Adney</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Scheuermann</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Pekosz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tarbet</surname><given-names>E.B.</given-names></name></person-group><article-title>Animal Models of Enterovirus D68 Infection and Disease</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e00833-22</fpage><pub-id pub-id-type="doi">10.1128/jvi.00833-22</pub-id><pub-id pub-id-type="pmid">35852353</pub-id><pub-id pub-id-type="pmcid">PMC9364802</pub-id></element-citation></ref><ref id="B63-idr-17-00061"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartlett</surname><given-names>N.W.</given-names></name><name name-style="western"><surname>Walton</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Aniscenko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caramori</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Glanville</surname><given-names>N.</given-names></name><name name-style="western"><surname>Choy</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Jourdan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Burnet</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Mouse Models of Rhinovirus-Induced Disease and Exacerbation of Allergic Airway Inflammation</article-title><source>Nat. Med.</source><year>2008</year><volume>14</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1038/nm1713</pub-id><pub-id pub-id-type="pmid">18246079</pub-id><pub-id pub-id-type="pmcid">PMC3384678</pub-id></element-citation></ref><ref id="B64-idr-17-00061"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singanayagam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Glanville</surname><given-names>N.</given-names></name><name name-style="western"><surname>Walton</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Aniscenko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Pinkerton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Horvat</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Hansbro</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>N.W.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>S.L.</given-names></name></person-group><article-title>A Short-Term Mouse Model That Reproduces the Immunopathological Features of Rhinovirus-Induced Exacerbation of COPD</article-title><source>Clin. Sci. Lond. Engl. 1979</source><year>2015</year><volume>129</volume><fpage>245</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1042/CS20140654</pub-id><pub-id pub-id-type="pmcid">PMC4557402</pub-id><pub-id pub-id-type="pmid">25783022</pub-id></element-citation></ref><ref id="B65-idr-17-00061"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toussaint</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Swieboda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gued&#225;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsourouktsoglou</surname><given-names>T.-D.</given-names></name><name name-style="western"><surname>Ching</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Radermecker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Makrinioti</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aniscenko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>N.W.</given-names></name><etal/></person-group><article-title>Host DNA Released by NETosis Promotes Rhinovirus-Induced Type-2 Allergic Asthma Exacerbation</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>681</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/nm.4332</pub-id><pub-id pub-id-type="pmid">28459437</pub-id><pub-id pub-id-type="pmcid">PMC5821220</pub-id></element-citation></ref><ref id="B66-idr-17-00061"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traub</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nikonova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carruthers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dunmore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vousden</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Gogsadze</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>An Anti-Human ICAM-1 Antibody Inhibits Rhinovirus-Induced Exacerbations of Lung Inflammation</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003520</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003520</pub-id><pub-id pub-id-type="pmid">23935498</pub-id><pub-id pub-id-type="pmcid">PMC3731244</pub-id></element-citation></ref><ref id="B67-idr-17-00061"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glanville</surname><given-names>N.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Guy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lecouturier</surname><given-names>V.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Girerd</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gregoire</surname><given-names>C.</given-names></name><name name-style="western"><surname>Walton</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Kebadze</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Cross-Serotype Immunity Induced by Immunization with a Conserved Rhinovirus Capsid Protein</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003669</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003669</pub-id><pub-id pub-id-type="pmid">24086140</pub-id><pub-id pub-id-type="pmcid">PMC3784482</pub-id></element-citation></ref><ref id="B68-idr-17-00061"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mombo</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Lukashev</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Bleicker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Br&#252;nink</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berthet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Maganga</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Durand</surname><given-names>P.</given-names></name><name name-style="western"><surname>Arnathau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boundenga</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ngoubangoye</surname><given-names>B.</given-names></name><etal/></person-group><article-title>African Non-Human Primates Host Diverse Enteroviruses</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0169067</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0169067</pub-id><pub-id pub-id-type="pmid">28081564</pub-id><pub-id pub-id-type="pmcid">PMC5233426</pub-id></element-citation></ref><ref id="B69-idr-17-00061"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sestak</surname><given-names>K.</given-names></name></person-group><article-title>Non-Human Primate Models of Enteric Viral Infections</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>544</elocation-id><pub-id pub-id-type="doi">10.3390/v10100544</pub-id><pub-id pub-id-type="pmid">30301125</pub-id><pub-id pub-id-type="pmcid">PMC6213648</pub-id></element-citation></ref><ref id="B70-idr-17-00061"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.-Z.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>R.-T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.-N.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.-T.</given-names></name><etal/></person-group><article-title>Nasal Infection of Enterovirus D68 Leading to Lower Respiratory Tract Pathogenesis in Ferrets (Mustela Putorius Furo)</article-title><source>Viruses</source><year>2017</year><volume>9</volume><elocation-id>104</elocation-id><pub-id pub-id-type="doi">10.3390/v9050104</pub-id><pub-id pub-id-type="pmid">28489053</pub-id><pub-id pub-id-type="pmcid">PMC5454417</pub-id></element-citation></ref><ref id="B71-idr-17-00061"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#252;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name></person-group><article-title>Medicinal Chemistry Strategies toward Broad-Spectrum Antiviral Agents to Prevent next Pandemics</article-title><source>Eur. J. Med. Chem.</source><year>2024</year><volume>271</volume><fpage>116442</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2024.116442</pub-id><pub-id pub-id-type="pmid">38685143</pub-id></element-citation></ref><ref id="B72-idr-17-00061"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Einav</surname><given-names>S.</given-names></name></person-group><article-title>Preparing for the next Viral Threat with Broad-Spectrum Antivirals</article-title><source>J. Clin. Invest.</source><year>2023</year><volume>133</volume><fpage>e170236</fpage><pub-id pub-id-type="doi">10.1172/JCI170236</pub-id><pub-id pub-id-type="pmid">37259914</pub-id><pub-id pub-id-type="pmcid">PMC10232003</pub-id></element-citation></ref><ref id="B73-idr-17-00061"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderlinden</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vrancken</surname><given-names>B.</given-names></name><name name-style="western"><surname>Van Houdt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rajwanshi</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Gillemot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andrei</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lemey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Naesens</surname><given-names>L.</given-names></name></person-group><article-title>Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>6679</fpage><lpage>6691</lpage><pub-id pub-id-type="doi">10.1128/AAC.01156-16</pub-id><pub-id pub-id-type="pmid">27572398</pub-id><pub-id pub-id-type="pmcid">PMC5075073</pub-id></element-citation></ref><ref id="B74-idr-17-00061"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geraghty</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Aliota</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Bonnac</surname><given-names>L.F.</given-names></name></person-group><article-title>Broad-Spectrum Antiviral Strategies and Nucleoside Analogues</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>667</elocation-id><pub-id pub-id-type="doi">10.3390/v13040667</pub-id><pub-id pub-id-type="pmid">33924302</pub-id><pub-id pub-id-type="pmcid">PMC8069527</pub-id></element-citation></ref><ref id="B75-idr-17-00061"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazear</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Schoggins</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name></person-group><article-title>Shared and Distinct Functions of Type I and Type III Interferons</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>907</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.025</pub-id><pub-id pub-id-type="pmid">30995506</pub-id><pub-id pub-id-type="pmcid">PMC6839410</pub-id></element-citation></ref><ref id="B76-idr-17-00061"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kejriwal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>T.</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>J.</given-names></name><name name-style="western"><surname>Swistak</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alexandrescu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Henriksen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Charan Dash</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hadden</surname><given-names>M.K.</given-names></name><etal/></person-group><article-title>Development of Enterovirus Antiviral Agents That Target the Viral 2C Protein</article-title><source>ChemMedChem</source><year>2023</year><volume>18</volume><fpage>e202200541</fpage><pub-id pub-id-type="doi">10.1002/cmdc.202200541</pub-id><pub-id pub-id-type="pmid">36792530</pub-id></element-citation></ref><ref id="B77-idr-17-00061"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobinska</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pilpel</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>M.A.</given-names></name></person-group><article-title>Evolutionary Safety of Lethal Mutagenesis Driven by Antiviral Treatment</article-title><source>PLoS Biol.</source><year>2023</year><volume>21</volume><elocation-id>e3002214</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3002214</pub-id><pub-id pub-id-type="pmid">37552682</pub-id><pub-id pub-id-type="pmcid">PMC10409280</pub-id></element-citation></ref><ref id="B78-idr-17-00061"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Synergistic Antiviral Activity of Gemcitabine and Ribavirin against Enteroviruses</article-title><source>Antiviral Res.</source><year>2015</year><volume>124</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.10.011</pub-id><pub-id pub-id-type="pmid">26526589</pub-id></element-citation></ref><ref id="B79-idr-17-00061"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fokine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Long</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Kihara</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rossmann</surname><given-names>M.G.</given-names></name></person-group><article-title>Structure and Inhibition of EV-D68, a Virus That Causes Respiratory Illness in Children</article-title><source>Science</source><year>2015</year><volume>347</volume><fpage>71</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.1261962</pub-id><pub-id pub-id-type="pmid">25554786</pub-id><pub-id pub-id-type="pmcid">PMC4307789</pub-id></element-citation></ref><ref id="B80-idr-17-00061"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Herrington</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Coats</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Villano</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pevear</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Collett</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of Oral Pleconaril for Treatment of Colds Due to Picornaviruses in Adults: Results of 2 Double-Blind, Randomized, Placebo-Controlled Trials</article-title><source>Clin. Infect. Dis.</source><year>2003</year><volume>36</volume><fpage>1523</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1086/375069</pub-id><pub-id pub-id-type="pmid">12802751</pub-id><pub-id pub-id-type="pmcid">PMC7199898</pub-id></element-citation></ref><ref id="B81-idr-17-00061"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senior</surname><given-names>K.</given-names></name></person-group><article-title>FDA Panel Rejects Common Cold Treatment</article-title><source>Lancet Infect. Dis.</source><year>2002</year><volume>2</volume><fpage>264</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(02)00277-3</pub-id><pub-id pub-id-type="pmid">12062983</pub-id></element-citation></ref><ref id="B82-idr-17-00061"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Andries</surname><given-names>K.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>P.A.</given-names></name></person-group><article-title>Safety and Efficacy of Intranasal Pirodavir (R77975) in Experimental Rhinovirus Infection</article-title><source>Antimicrob. Agents Chemother.</source><year>1992</year><volume>36</volume><fpage>727</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1128/AAC.36.4.727</pub-id><pub-id pub-id-type="pmid">1503435</pub-id><pub-id pub-id-type="pmcid">PMC189373</pub-id></element-citation></ref><ref id="B83-idr-17-00061"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Hipskind</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Woerner</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Andries</surname><given-names>K.</given-names></name></person-group><article-title>Intranasal Pirodavir (R77,975) Treatment of Rhinovirus Colds</article-title><source>Antimicrob. Agents Chemother.</source><year>1995</year><volume>39</volume><fpage>290</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1128/AAC.39.2.290</pub-id><pub-id pub-id-type="pmid">7726484</pub-id><pub-id pub-id-type="pmcid">PMC162529</pub-id></element-citation></ref><ref id="B84-idr-17-00061"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoyanova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galabov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galabov</surname><given-names>A.S.</given-names></name></person-group><article-title>Antiviral Activity in Vitro of Double Combinations of Enteroviral Inhibitors</article-title><source>Acta Virol.</source><year>2024</year><volume>68</volume><fpage>12361</fpage><pub-id pub-id-type="doi">10.3389/av.2024.12361</pub-id></element-citation></ref><ref id="B85-idr-17-00061"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amdani</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Orvedahl</surname><given-names>A.</given-names></name><name name-style="western"><surname>John</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Said</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>K.</given-names></name></person-group><article-title>Successful Treatment of Fulminant Neonatal Enteroviral Myocarditis in Monochorionic Diamniotic Twins with Cardiopulmonary Support, Intravenous Immunoglobulin and Pocapavir</article-title><source>BMJ Case Rep.</source><year>2018</year><volume>2018</volume><fpage>bcr-2017-224133</fpage><pub-id pub-id-type="doi">10.1136/bcr-2017-224133</pub-id><pub-id pub-id-type="pmid">29776940</pub-id><pub-id pub-id-type="pmcid">PMC5965763</pub-id></element-citation></ref><ref id="B86-idr-17-00061"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Real-Hohn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blaas</surname><given-names>D.</given-names></name></person-group><article-title>Rhinovirus Inhibitors: Including a New Target, the Viral RNA</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1784</elocation-id><pub-id pub-id-type="doi">10.3390/v13091784</pub-id><pub-id pub-id-type="pmid">34578365</pub-id><pub-id pub-id-type="pmcid">PMC8473194</pub-id></element-citation></ref><ref id="B87-idr-17-00061"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Discovery and Optimization of Quinoline Analogues as Novel Potent Antivirals against Enterovirus D68</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><fpage>14792</fpage><lpage>14808</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01311</pub-id><pub-id pub-id-type="pmid">36254462</pub-id><pub-id pub-id-type="pmcid">PMC9661475</pub-id></element-citation></ref><ref id="B88-idr-17-00061"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Musharrafieh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68</article-title><source>ACS Infect. Dis.</source><year>2019</year><volume>5</volume><fpage>1952</fpage><lpage>1962</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00284</pub-id><pub-id pub-id-type="pmid">31532189</pub-id><pub-id pub-id-type="pmcid">PMC7167248</pub-id></element-citation></ref><ref id="B89-idr-17-00061"><label>89.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Biota Pharmaceuticals, Inc.</collab></person-group><article-title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection. Clinical Trials for Eudract_number:2014-001785-95</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001785-95" ext-link-type="uri">https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001785-95</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-18">(accessed on 18 March 2025)</date-in-citation></element-citation></ref><ref id="B90-idr-17-00061"><label>90.</label><element-citation publication-type="book"><std><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06149494">NCT06149494</ext-link></std><source>RCT of Vapendavir in Patients with COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection</source><publisher-name>Altesa Biosciences, Inc.</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06149494" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06149494</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-07">(accessed on 7 May 2025)</date-in-citation></element-citation></ref><ref id="B91-idr-17-00061"><label>91.</label><element-citation publication-type="gov"><article-title>China Daily Domestically Developed Drug Joins Virus Battle</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://english.nmpa.gov.cn/2022-08/15/c_797867.htm" ext-link-type="uri">https://english.nmpa.gov.cn/2022-08/15/c_797867.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-18">(accessed on 18 March 2025)</date-in-citation></element-citation></ref><ref id="B92-idr-17-00061"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>1142</elocation-id><pub-id pub-id-type="doi">10.3390/v14061142</pub-id><pub-id pub-id-type="pmid">35746614</pub-id><pub-id pub-id-type="pmcid">PMC9227765</pub-id></element-citation></ref><ref id="B93-idr-17-00061"><label>93.</label><element-citation publication-type="book"><source>Medicines and Healthcare Products Regulatory Agency (MHRA) First Oral Antiviral for COVID-19, Lagevrio (Molnupiravir)</source><publisher-name>MHRA</publisher-name><publisher-loc>London, UK</publisher-loc><year>2021</year></element-citation></ref><ref id="B94-idr-17-00061"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Manganaro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zonsics</surname><given-names>B.</given-names></name><name name-style="western"><surname>Strating</surname><given-names>J.R.P.M.</given-names></name><name name-style="western"><surname>El Kazzi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lorenzo Lopez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ulferts</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Hoey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mat&#233;</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Fluoxetine Inhibits Enterovirus Replication by Targeting the Viral 2C Protein in a Stereospecific Manner</article-title><source>ACS Infect. Dis.</source><year>2019</year><volume>5</volume><fpage>1609</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00179</pub-id><pub-id pub-id-type="pmid">31305993</pub-id><pub-id pub-id-type="pmcid">PMC6747591</pub-id></element-citation></ref><ref id="B95-idr-17-00061"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messacar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sillau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Otten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wilson-Murphy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Treister</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tokhie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.</given-names></name><etal/></person-group><article-title>1901. Safety, Tolerability, and Efficacy of Fluoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study</article-title><source>Open Forum Infect. Dis.</source><year>2018</year><volume>5</volume><fpage>S546</fpage><lpage>S547</lpage><pub-id pub-id-type="doi">10.1093/ofid/ofy210.1557</pub-id></element-citation></ref><ref id="B96-idr-17-00061"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hurst</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Smee</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Van Wettere</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Tarbet</surname><given-names>E.B.</given-names></name></person-group><article-title>Evaluation of Antiviral Therapies in Respiratory and Neurological Disease Models of Enterovirus D68 Infection in Mice</article-title><source>Virology</source><year>2019</year><volume>526</volume><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2018.10.014</pub-id><pub-id pub-id-type="pmid">30390563</pub-id><pub-id pub-id-type="pmcid">PMC6309259</pub-id></element-citation></ref><ref id="B97-idr-17-00061"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Hruska</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Betts</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>W.J.</given-names></name></person-group><article-title>Ribavirin Treatment of Experimental Respiratory Syncytial Viral Infection. A Controlled Double-Blind Study in Young Adults</article-title><source>JAMA</source><year>1983</year><volume>249</volume><fpage>2666</fpage><lpage>2670</lpage><pub-id pub-id-type="doi">10.1001/jama.1983.03330430042027</pub-id><pub-id pub-id-type="pmid">6341640</pub-id></element-citation></ref><ref id="B98-idr-17-00061"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casanova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>P.G.</given-names></name></person-group><article-title>Antiviral Therapeutic Approaches for Human Rhinovirus Infections</article-title><source>Future Virol.</source><year>2018</year><volume>13</volume><fpage>505</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.2217/fvl-2018-0016</pub-id><pub-id pub-id-type="pmid">30245735</pub-id><pub-id pub-id-type="pmcid">PMC6136076</pub-id></element-citation></ref><ref id="B99-idr-17-00061"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nystr&#246;m</surname><given-names>K.</given-names></name><name name-style="western"><surname>Waldenstr&#246;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>K.-W.</given-names></name><name name-style="western"><surname>Lagging</surname><given-names>M.</given-names></name></person-group><article-title>Ribavirin: Pharmacology, Multiple Modes of Action and Possible Future Perspectives</article-title><source>Future Virol.</source><year>2019</year><volume>14</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.2217/fvl-2018-0166</pub-id></element-citation></ref><ref id="B100-idr-17-00061"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhoden</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nix</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Oberste</surname><given-names>M.S.</given-names></name></person-group><article-title>In Vitro Efficacy of Antiviral Compounds against Enterovirus D68</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>7779</fpage><lpage>7781</lpage><pub-id pub-id-type="doi">10.1128/AAC.00766-15</pub-id><pub-id pub-id-type="pmid">26149998</pub-id><pub-id pub-id-type="pmcid">PMC4649146</pub-id></element-citation></ref><ref id="B101-idr-17-00061"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Gwaltney</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chi-Burris</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gersten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hsyu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Patick</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Zalman</surname><given-names>L.S.</given-names></name></person-group><article-title>Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers</article-title><source>Antimicrob. Agents Chemother.</source><year>2003</year><volume>47</volume><fpage>3907</fpage><lpage>3916</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.12.3907-3916.2003</pub-id><pub-id pub-id-type="pmid">14638501</pub-id><pub-id pub-id-type="pmcid">PMC296196</pub-id></element-citation></ref><ref id="B102-idr-17-00061"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musharrafieh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Diesing</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Marty</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Validating Enterovirus D68-2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2Apro Inhibitor</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>e02221-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.02221-18</pub-id><pub-id pub-id-type="pmid">30674624</pub-id><pub-id pub-id-type="pmcid">PMC6430540</pub-id></element-citation></ref><ref id="B103-idr-17-00061"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rudy</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Leser</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>K.L.</given-names></name></person-group><article-title>Telaprevir Treatment Reduces Paralysis in a Mouse Model of Enterovirus D68 Acute Flaccid Myelitis</article-title><source>J. Virol.</source><year>2023</year><volume>97</volume><fpage>e0015623</fpage><pub-id pub-id-type="doi">10.1128/jvi.00156-23</pub-id><pub-id pub-id-type="pmid">37154751</pub-id><pub-id pub-id-type="pmcid">PMC10231134</pub-id></element-citation></ref><ref id="B104-idr-17-00061"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kankam</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Collett</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Corrado</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Hincks</surname><given-names>J.R.</given-names></name></person-group><article-title>A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers</article-title><source>Antimicrob. Agents Chemother.</source><year>2021</year><volume>65</volume><fpage>e01029-21</fpage><pub-id pub-id-type="doi">10.1128/AAC.01029-21</pub-id><pub-id pub-id-type="pmid">34370575</pub-id><pub-id pub-id-type="pmcid">PMC8448163</pub-id></element-citation></ref><ref id="B105-idr-17-00061"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gued&#225;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Swieboda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Asfor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panjwani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tuthill</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Danahay</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raynham</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Investigation of the Role of Protein Kinase D in Human Rhinovirus Replication</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e00217-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.00217-17</pub-id><pub-id pub-id-type="pmid">28228588</pub-id><pub-id pub-id-type="pmcid">PMC5391474</pub-id></element-citation></ref><ref id="B106-idr-17-00061"><label>106.</label><element-citation publication-type="book"><std><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05016687">NCT05016687</ext-link></std><source>First-in-Human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers</source><publisher-name>Curovir AB</publisher-name><publisher-loc>Kalmar, Sweden</publisher-loc><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05016687" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05016687</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-07">(accessed on 7 May 2025)</date-in-citation></element-citation></ref><ref id="B107-idr-17-00061"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvatore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Satlin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Van Besien</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shore</surname><given-names>T.</given-names></name><name name-style="western"><surname>Soave</surname><given-names>R.</given-names></name></person-group><article-title>DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center</article-title><source>Biol. Blood Marrow Transplant.</source><year>2016</year><volume>22</volume><fpage>965</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2016.02.011</pub-id><pub-id pub-id-type="pmid">26904972</pub-id></element-citation></ref><ref id="B108-idr-17-00061"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marjuki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mishin</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Chesnokov</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>De La Cruz</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fry</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gubareva</surname><given-names>L.V.</given-names></name></person-group><article-title>An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza A Virus Subtype H7N9 and Protects Mice from Lethality</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>210</volume><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu105</pub-id><pub-id pub-id-type="pmid">24569063</pub-id><pub-id pub-id-type="pmcid">PMC4091581</pub-id></element-citation></ref><ref id="B109-idr-17-00061"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Froeyen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thibaut</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Baggen</surname><given-names>J.</given-names></name><name name-style="western"><surname>George</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vernachio</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Kuppeveld</surname><given-names>F.J.M.</given-names></name><name name-style="western"><surname>Leyssen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>7782</fpage><lpage>7785</lpage><pub-id pub-id-type="doi">10.1128/AAC.01375-15</pub-id><pub-id pub-id-type="pmid">26369972</pub-id><pub-id pub-id-type="pmcid">PMC4649165</pub-id></element-citation></ref><ref id="B110-idr-17-00061"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Monto</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>DeLong</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Exelby</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name></person-group><article-title>Controlled Trial of Enviroxime against Natural Rhinovirus Infections in a Community</article-title><source>Antimicrob. Agents Chemother.</source><year>1985</year><volume>27</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1128/AAC.27.1.102</pub-id><pub-id pub-id-type="pmid">2984980</pub-id><pub-id pub-id-type="pmcid">PMC176213</pub-id></element-citation></ref><ref id="B111-idr-17-00061"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smee</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Nicolaou</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Tarbet</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Day</surname><given-names>C.W.</given-names></name></person-group><article-title>Susceptibilities of Enterovirus D68, Enterovirus 71, and Rhinovirus 87 Strains to Various Antiviral Compounds</article-title><source>Antiviral Res.</source><year>2016</year><volume>131</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.04.003</pub-id><pub-id pub-id-type="pmid">27063860</pub-id><pub-id pub-id-type="pmcid">PMC5100981</pub-id></element-citation></ref><ref id="B112-idr-17-00061"><label>112.</label><element-citation publication-type="book"><std><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05677347">NCT05677347</ext-link></std><source>Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants with Chronic Obstructive Pulmonary Disease (COPD)</source><publisher-name>GlaxoSmithKline</publisher-name><publisher-loc>London, UK</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05677347?rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05677347?rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-14">(accessed on 14 May 2025)</date-in-citation></element-citation></ref><ref id="B113-idr-17-00061"><label>113.</label><element-citation publication-type="book"><std><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04585009">NCT04585009</ext-link></std><source>Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics</source><publisher-name>GlaxoSmithKline</publisher-name><publisher-loc>London, UK</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04585009?rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04585009?rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-14">(accessed on 14 May 2025)</date-in-citation></element-citation></ref><ref id="B114-idr-17-00061"><label>114.</label><element-citation publication-type="book"><std><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05398198">NCT05398198</ext-link></std><source>Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma</source><publisher-name>GlaxoSmithKline</publisher-name><publisher-loc>London, UK</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05398198" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05398198</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-07">(accessed on 7 May 2025)</date-in-citation></element-citation></ref><ref id="B115-idr-17-00061"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>B.-E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>K.-J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-S.</given-names></name><etal/></person-group><article-title>Therapeutic and Prophylactic Activity of Itraconazole against Human Rhinovirus Infection in a Murine Model</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>23110</elocation-id><pub-id pub-id-type="doi">10.1038/srep23110</pub-id><pub-id pub-id-type="pmid">26976677</pub-id><pub-id pub-id-type="pmcid">PMC4791555</pub-id></element-citation></ref><ref id="B116-idr-17-00061"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strating</surname><given-names>J.R.P.M.</given-names></name><name name-style="western"><surname>van der Linden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Albulescu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bigay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leyssen</surname><given-names>P.</given-names></name><name name-style="western"><surname>van der Schaar</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Lanke</surname><given-names>K.H.W.</given-names></name><name name-style="western"><surname>Thibaut</surname><given-names>H.J.</given-names></name><etal/></person-group><article-title>Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein</article-title><source>Cell Rep.</source><year>2015</year><volume>10</volume><fpage>600</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.12.054</pub-id><pub-id pub-id-type="pmid">25640182</pub-id><pub-id pub-id-type="pmcid">PMC4383725</pub-id></element-citation></ref><ref id="B117-idr-17-00061"><label>117.</label><element-citation publication-type="book"><std><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04908800">NCT04908800</ext-link></std><source>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects</source><publisher-name>Kyorin Pharmaceutical Co.,Ltd.</publisher-name><publisher-loc>Tokyo, Japan</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04908800" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04908800</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-07">(accessed on 7 May 2025)</date-in-citation></element-citation></ref><ref id="B118-idr-17-00061"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>SAMHD1 Inhibits Multiple Enteroviruses by Interfering with the Interaction between VP1 and VP2 Proteins</article-title><source>J. Virol.</source><year>2021</year><volume>95</volume><fpage>e0062021</fpage><pub-id pub-id-type="doi">10.1128/JVI.00620-21</pub-id><pub-id pub-id-type="pmid">33883225</pub-id><pub-id pub-id-type="pmcid">PMC8316000</pub-id></element-citation></ref><ref id="B119-idr-17-00061"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laajala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zwaagstra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martikainen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nekoua</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Benkahla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sane</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gervais</surname><given-names>E.</given-names></name><name name-style="western"><surname>Campagnola</surname><given-names>G.</given-names></name><name name-style="western"><surname>Honkimaa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sioofy-Khojine</surname><given-names>A.-B.</given-names></name><etal/></person-group><article-title>Vemurafenib Inhibits Acute and Chronic Enterovirus Infection by Affecting Cellular Kinase Phosphatidylinositol 4-Kinase Type III&#946;</article-title><source>Microbiol. Spectr.</source><year>2023</year><volume>11</volume><fpage>e00552-23</fpage><pub-id pub-id-type="doi">10.1128/spectrum.00552-23</pub-id><pub-id pub-id-type="pmid">37436162</pub-id><pub-id pub-id-type="pmcid">PMC10433971</pub-id></element-citation></ref><ref id="B120-idr-17-00061"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A Novel Neutralizing Antibody Specific to the DE Loop of VP1 Can Inhibit EV-D68 Infection in Mice</article-title><source>J. Immunol. Baltim. Md 1950</source><year>2018</year><volume>201</volume><fpage>2557</fpage><lpage>2569</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1800655</pub-id><pub-id pub-id-type="pmid">30282753</pub-id></element-citation></ref><ref id="B121-idr-17-00061"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogt</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Bombardi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Setliff</surname><given-names>I.</given-names></name><name name-style="western"><surname>Georgiev</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Klose</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rossmann</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Hurst</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Human Antibodies Neutralize Enterovirus D68 and Protect against Infection and Paralytic Disease</article-title><source>Sci. Immunol.</source><year>2020</year><volume>5</volume><fpage>eaba4902</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aba4902</pub-id><pub-id pub-id-type="pmid">32620559</pub-id><pub-id pub-id-type="pmcid">PMC7418079</pub-id></element-citation></ref><ref id="B122-idr-17-00061"><label>122.</label><element-citation publication-type="book"><std><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06444048">NCT06444048</ext-link></std><source>Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-Specific Monoclonal Antibody in Healthy Adults</source><publisher-name>National Institute of Allergy and Infectious Diseases (NIAID)</publisher-name><publisher-loc>Hamilton, MO, USA</publisher-loc><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06444048" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06444048</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-18">(accessed on 18 March 2025)</date-in-citation></element-citation></ref><ref id="B123-idr-17-00061"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pevear</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Tull</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Seipel</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Groarke</surname><given-names>J.M.</given-names></name></person-group><article-title>Activity of Pleconaril against Enteroviruses</article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>2109</fpage><lpage>2115</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.9.2109</pub-id><pub-id pub-id-type="pmid">10471549</pub-id><pub-id pub-id-type="pmcid">PMC89431</pub-id></element-citation></ref><ref id="B124-idr-17-00061"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abzug</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Michaels</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Wald</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Krogstad</surname><given-names>P.</given-names></name><name name-style="western"><surname>Storch</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2016</year><volume>5</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1093/jpids/piv015</pub-id><pub-id pub-id-type="pmcid">PMC4765488</pub-id><pub-id pub-id-type="pmid">26407253</pub-id></element-citation></ref><ref id="B125-idr-17-00061"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feil</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krippner</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luttick</surname><given-names>A.</given-names></name><name name-style="western"><surname>McConnell</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Nearn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stanislawski</surname><given-names>P.C.</given-names></name><etal/></person-group><article-title>An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus</article-title><source>ACS Med. Chem. Lett.</source><year>2012</year><volume>3</volume><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1021/ml2002955</pub-id><pub-id pub-id-type="pmid">24900468</pub-id><pub-id pub-id-type="pmcid">PMC4025830</pub-id></element-citation></ref><ref id="B126-idr-17-00061"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Torres</surname><given-names>S.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Klatte</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rhoden</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Oberste</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Collett</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>McCulloh</surname><given-names>R.J.</given-names></name></person-group><article-title>First Use of Investigational Antiviral Drug Pocapavir (V-073) for Treating Neonatal Enteroviral Sepsis</article-title><source>Pediatr. Infect. Dis. J.</source><year>2015</year><volume>34</volume><fpage>52</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000000497</pub-id><pub-id pub-id-type="pmid">25229269</pub-id></element-citation></ref><ref id="B127-idr-17-00061"><label>127.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Danielsen</surname><given-names>C.</given-names></name></person-group><article-title>P58 An Antiviral Dilemma&#8212;Reflections on the Pocapavir Predicament</article-title><source>Proceedings of the Abstracts form the Neonatal and Paediatric Pharmacy Conference 2023</source><publisher-name>BMJ Publishing Group Ltd.</publisher-name><publisher-loc>Cheshire, UK</publisher-loc><year>2024</year><fpage>A38</fpage><lpage>A39</lpage></element-citation></ref><ref id="B128-idr-17-00061"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magden</surname><given-names>J.</given-names></name><name name-style="western"><surname>K&#228;&#228;ri&#228;inen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ahola</surname><given-names>T.</given-names></name></person-group><article-title>Inhibitors of Virus Replication: Recent Developments and Prospects</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2005</year><volume>66</volume><fpage>612</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1007/s00253-004-1783-3</pub-id><pub-id pub-id-type="pmid">15592828</pub-id><pub-id pub-id-type="pmcid">PMC7082807</pub-id></element-citation></ref><ref id="B129-idr-17-00061"><label>129.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>FDA</collab></person-group><source>INCIVEK<sup>&#174;</sup> (Telaprevir) Tablets, for Oral Use</source><publisher-name>Food and Drug Administration</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B130-idr-17-00061"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Antiviral Effects of Simeprevir on Multiple Viruses</article-title><source>Antiviral Res.</source><year>2019</year><volume>172</volume><fpage>104607</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104607</pub-id><pub-id pub-id-type="pmid">31563599</pub-id></element-citation></ref><ref id="B131-idr-17-00061"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.-C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Human Enterovirus Nonstructural Protein 2CATPase Functions as Both an RNA Helicase and ATP-Independent RNA Chaperone</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1005067</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005067</pub-id><pub-id pub-id-type="pmid">26218680</pub-id><pub-id pub-id-type="pmcid">PMC4517893</pub-id></element-citation></ref><ref id="B132-idr-17-00061"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyler</surname><given-names>K.L.</given-names></name></person-group><article-title>Rationale for the Evaluation of Fluoxetine in the Treatment of Enterovirus D68-Associated Acute Flaccid Myelitis</article-title><source>JAMA Neurol.</source><year>2015</year><volume>72</volume><fpage>493</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2014.4625</pub-id><pub-id pub-id-type="pmid">25775436</pub-id><pub-id pub-id-type="pmcid">PMC5086417</pub-id></element-citation></ref><ref id="B133-idr-17-00061"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulferts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Der Linden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thibaut</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lanke</surname><given-names>K.H.W.</given-names></name><name name-style="western"><surname>Leyssen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Coutard</surname><given-names>B.</given-names></name><name name-style="western"><surname>De Palma</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Canard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Neyts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Kuppeveld</surname><given-names>F.J.M.</given-names></name></person-group><article-title>Selective Serotonin Reuptake Inhibitor Fluoxetine Inhibits Replication of Human Enteroviruses B and D by Targeting Viral Protein 2C</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>1952</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.1128/AAC.02084-12</pub-id><pub-id pub-id-type="pmid">23335743</pub-id><pub-id pub-id-type="pmcid">PMC3623316</pub-id></element-citation></ref><ref id="B134-idr-17-00061"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hixon</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>K.L.</given-names></name></person-group><article-title>Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68&#8211;Associated Paralytic Myelitis</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>216</volume><fpage>1245</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix468</pub-id><pub-id pub-id-type="pmid">28968718</pub-id><pub-id pub-id-type="pmcid">PMC5853295</pub-id></element-citation></ref><ref id="B135-idr-17-00061"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gofshteyn</surname><given-names>J.</given-names></name><name name-style="western"><surname>C&#225;rdenas</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bearden</surname><given-names>D.</given-names></name></person-group><article-title>Treatment of Chronic Enterovirus Encephalitis With Fluoxetine in a Patient With X-Linked Agammaglobulinemia</article-title><source>Pediatr. Neurol.</source><year>2016</year><volume>64</volume><fpage>94</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2016.06.014</pub-id><pub-id pub-id-type="pmid">27640319</pub-id></element-citation></ref><ref id="B136-idr-17-00061"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patick</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Binford</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Brothers</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Diem</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dragovich</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Prins</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease</article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>2444</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.10.2444</pub-id><pub-id pub-id-type="pmid">10508022</pub-id><pub-id pub-id-type="pmcid">PMC89498</pub-id></element-citation></ref><ref id="B137-idr-17-00061"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>e00204-20</fpage><pub-id pub-id-type="doi">10.1128/JVI.00204-20</pub-id><pub-id pub-id-type="pmid">32075935</pub-id><pub-id pub-id-type="pmcid">PMC7163137</pub-id></element-citation></ref><ref id="B138-idr-17-00061"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Esteban-Mur</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rustgi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hoefs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Trepo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shiffman</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Zeuzem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Craxi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>M.-H.</given-names></name><etal/></person-group><article-title>Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C</article-title><source>N. Engl. J. Med.</source><year>1998</year><volume>339</volume><fpage>1493</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1056/NEJM199811193392102</pub-id><pub-id pub-id-type="pmid">9819447</pub-id></element-citation></ref><ref id="B139-idr-17-00061"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Te</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>D.M.</given-names></name></person-group><article-title>Mechanism of Action of Ribavirin in the Treatment of Chronic Hepatitis C</article-title><source>Gastroenterol. Hepatol.</source><year>2007</year><volume>3</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="pmcid">PMC3099343</pub-id><pub-id pub-id-type="pmid">21960835</pub-id></element-citation></ref><ref id="B140-idr-17-00061"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crotty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Andino</surname><given-names>R.</given-names></name></person-group><article-title>RNA Virus Error Catastrophe: Direct Molecular Test by Using Ribavirin</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>6895</fpage><lpage>6900</lpage><pub-id pub-id-type="doi">10.1073/pnas.111085598</pub-id><pub-id pub-id-type="pmid">11371613</pub-id><pub-id pub-id-type="pmcid">PMC34449</pub-id></element-citation></ref><ref id="B141-idr-17-00061"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leyssen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Balzarini</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Clercq</surname><given-names>E.</given-names></name><name name-style="western"><surname>Neyts</surname><given-names>J.</given-names></name></person-group><article-title>The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>1943</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.3.1943-1947.2005</pub-id><pub-id pub-id-type="pmid">15650220</pub-id><pub-id pub-id-type="pmcid">PMC544097</pub-id></element-citation></ref><ref id="B142-idr-17-00061"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruuskanen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Waris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kainulainen</surname><given-names>L.</given-names></name></person-group><article-title>Treatment of Persistent Rhinovirus Infection with Pegylated Interferon A2a and Ribavirin in Patients with Hypogammaglobulinemia</article-title><source>Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.</source><year>2014</year><volume>58</volume><fpage>1784</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu169</pub-id><pub-id pub-id-type="pmid">24633687</pub-id><pub-id pub-id-type="pmcid">PMC7108044</pub-id></element-citation></ref><ref id="B143-idr-17-00061"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Pruijssers</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Agostini</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice</article-title><source>Sci. Transl. Med.</source><year>2020</year><volume>12</volume><fpage>eabb5883</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abb5883</pub-id><pub-id pub-id-type="pmid">32253226</pub-id><pub-id pub-id-type="pmcid">PMC7164393</pub-id></element-citation></ref><ref id="B144-idr-17-00061"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Syed</surname><given-names>Y.Y.</given-names></name></person-group><article-title>Molnupiravir: First Approval</article-title><source>Drugs</source><year>2022</year><volume>82</volume><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1007/s40265-022-01684-5</pub-id><pub-id pub-id-type="pmid">35184266</pub-id><pub-id pub-id-type="pmcid">PMC8858220</pub-id></element-citation></ref><ref id="B145-idr-17-00061"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coggins</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Mahboubi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schinazi</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name></person-group><article-title>SAMHD1 Functions and Human Diseases</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>382</elocation-id><pub-id pub-id-type="doi">10.3390/v12040382</pub-id><pub-id pub-id-type="pmid">32244340</pub-id><pub-id pub-id-type="pmcid">PMC7232136</pub-id></element-citation></ref><ref id="B146-idr-17-00061"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laguette</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sobhian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Casartelli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ringeard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chable-Bessia</surname><given-names>C.</given-names></name><name name-style="western"><surname>S&#233;g&#233;ral</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yatim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Emiliani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Benkirane</surname><given-names>M.</given-names></name></person-group><article-title>SAMHD1 Is the Dendritic- and Myeloid-Cell-Specific HIV-1 Restriction Factor Counteracted by Vpx</article-title><source>Nature</source><year>2011</year><volume>474</volume><fpage>654</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1038/nature10117</pub-id><pub-id pub-id-type="pmid">21613998</pub-id><pub-id pub-id-type="pmcid">PMC3595993</pub-id></element-citation></ref><ref id="B147-idr-17-00061"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Schaar</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>van der Linden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lanke</surname><given-names>K.H.W.</given-names></name><name name-style="western"><surname>Strating</surname><given-names>J.R.P.M.</given-names></name><name name-style="western"><surname>P&#252;rstinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Haan</surname><given-names>C.A.M.</given-names></name><name name-style="western"><surname>Neyts</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Kuppeveld</surname><given-names>F.J.M.</given-names></name></person-group><article-title>Coxsackievirus Mutants That Can Bypass Host Factor PI4KIII&#946; and the Need for High Levels of PI4P Lipids for Replication</article-title><source>Cell Res.</source><year>2012</year><volume>22</volume><fpage>1576</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1038/cr.2012.129</pub-id><pub-id pub-id-type="pmid">22945356</pub-id><pub-id pub-id-type="pmcid">PMC3494396</pub-id></element-citation></ref><ref id="B148-idr-17-00061"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammond</surname><given-names>G.R.V.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.E.</given-names></name></person-group><article-title>Novel Roles of Phosphoinositides in Signaling, Lipid Transport, and Disease</article-title><source>Curr. Opin. Cell Biol.</source><year>2020</year><volume>63</volume><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2019.12.007</pub-id><pub-id pub-id-type="pmid">31972475</pub-id><pub-id pub-id-type="pmcid">PMC7247936</pub-id></element-citation></ref><ref id="B149-idr-17-00061"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillpotts</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Delong</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tyrrell</surname><given-names>D.A.</given-names></name></person-group><article-title>The Activity of Enviroxime against Rhinovirus Infection in Man</article-title><source>Lancet Lond. Engl.</source><year>1981</year><volume>1</volume><fpage>1342</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(81)92520-4</pub-id><pub-id pub-id-type="pmid">6113314</pub-id></element-citation></ref><ref id="B150-idr-17-00061"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baggen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thibaut</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Van Kuppeveld</surname><given-names>F.J.M.</given-names></name><name name-style="western"><surname>Rossmann</surname><given-names>M.G.</given-names></name></person-group><article-title>Sialic Acid-Dependent Cell Entry of Human Enterovirus D68</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>8865</fpage><pub-id pub-id-type="doi">10.1038/ncomms9865</pub-id><pub-id pub-id-type="pmid">26563423</pub-id><pub-id pub-id-type="pmcid">PMC4660200</pub-id></element-citation></ref><ref id="B151-idr-17-00061"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Shastri</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Vanka</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Jha</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Dureja</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chellappan</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Dua</surname><given-names>K.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>E.H.</given-names></name></person-group><article-title>Targeting Intercellular Adhesion Molecule-1 (ICAM-1) to Reduce Rhinovirus-Induced Acute Exacerbations in Chronic Respiratory Diseases</article-title><source>Inflammopharmacology</source><year>2022</year><volume>30</volume><fpage>725</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1007/s10787-022-00968-2</pub-id><pub-id pub-id-type="pmid">35316427</pub-id><pub-id pub-id-type="pmcid">PMC8938636</pub-id></element-citation></ref><ref id="B152-idr-17-00061"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whiteman</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Spiteri</surname><given-names>M.A.</given-names></name></person-group><article-title>Expression of Intercellular Adhesion Molecule-1 (ICAM-1) in Nasal Epithelial Cells of Atopic Subjects: A Mechanism for Increased Rhinovirus Infection?</article-title><source>Clin. Exp. Immunol.</source><year>2000</year><volume>121</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01301.x</pub-id><pub-id pub-id-type="pmid">10931151</pub-id><pub-id pub-id-type="pmcid">PMC1905704</pub-id></element-citation></ref><ref id="B153-idr-17-00061"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krug</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.-P.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>EV-D68 Virus-like Particle Vaccines Elicit Cross-Clade Neutralizing Antibodies That Inhibit Infection and Block Dissemination</article-title><source>Sci. Adv.</source><year>2023</year><volume>9</volume><fpage>eadg6076</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adg6076</pub-id><pub-id pub-id-type="pmid">37196074</pub-id><pub-id pub-id-type="pmcid">PMC10191429</pub-id></element-citation></ref><ref id="B154-idr-17-00061"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Enterovirus D68 Virus-like Particles Expressed in <italic toggle="yes">Pichia Pastoris</italic> Potently Induce Neutralizing Antibody Responses and Confer Protection against Lethal Viral Infection in Mice</article-title><source>Emerg. Microbes Infect.</source><year>2018</year><volume>7</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/s41426-017-0005-x</pub-id><pub-id pub-id-type="pmid">29323105</pub-id><pub-id pub-id-type="pmcid">PMC5837163</pub-id></element-citation></ref><ref id="B155-idr-17-00061"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name></person-group><article-title>A Mouse Model of Enterovirus D68 Infection for Assessment of the Efficacy of Inactivated Vaccine</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.3390/v10020058</pub-id><pub-id pub-id-type="pmid">29385753</pub-id><pub-id pub-id-type="pmcid">PMC5850365</pub-id></element-citation></ref><ref id="B156-idr-17-00061"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name></person-group><article-title>A Virus-like Particle Vaccine Confers Protection against Enterovirus D68 Lethal Challenge in Mice</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.12.057</pub-id><pub-id pub-id-type="pmid">29295756</pub-id></element-citation></ref><ref id="B157-idr-17-00061"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pletneva</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Rajagopala</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hartert</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Boukhvalova</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J.C.G.</given-names></name></person-group><article-title>Enterovirus D-68 Infection, Prophylaxis, and Vaccination in a Novel Permissive Animal Model, the Cotton Rat (Sigmodon Hispidus)</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0166336</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0166336</pub-id><pub-id pub-id-type="pmid">27814404</pub-id><pub-id pub-id-type="pmcid">PMC5096705</pub-id></element-citation></ref><ref id="B158-idr-17-00061"><label>158.</label><element-citation publication-type="gov"><article-title>NCBI Datasets Kunming (KM) Strain&#8212;Enterovirus D68 Isolate RVL_KM201703 Polyprotein Gene, Partial Cds&#8212;MG991260</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/search/all/?term=MG991260" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/search/all/?term=MG991260</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-18">(accessed on 18 March 2025)</date-in-citation></element-citation></ref><ref id="B159-idr-17-00061"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behzadi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duehr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feyznezhad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schotsaert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nachbagauer</surname><given-names>R.</given-names></name></person-group><article-title>A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>9750</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-66600-x</pub-id><pub-id pub-id-type="pmid">32546721</pub-id><pub-id pub-id-type="pmcid">PMC7297972</pub-id></element-citation></ref><ref id="B160-idr-17-00061"><label>160.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Grady</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bruner</surname><given-names>P.J.</given-names></name></person-group><article-title>Polio Vaccine</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><pub-id pub-id-type="pmid">30252295</pub-id></element-citation></ref><ref id="B161-idr-17-00061"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P.-Y.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>K.-T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>B.-L.</given-names></name></person-group><article-title>A Novel Mucosal Bivalent Vaccine of EV-A71/EV-D68 Adjuvanted with Polysaccharides from Ganoderma Lucidum Protects Mice against EV-A71 and EV-D68 Lethal Challenge</article-title><source>J. Biomed. Sci.</source><year>2023</year><volume>30</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-023-00987-3</pub-id><pub-id pub-id-type="pmid">38110940</pub-id><pub-id pub-id-type="pmcid">PMC10729491</pub-id></element-citation></ref><ref id="B162-idr-17-00061"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenfeld</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>E.Q.L.</given-names></name><name name-style="western"><surname>Melendez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lipkin</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Racaniello</surname><given-names>V.R.</given-names></name></person-group><article-title>Cross-Reactive Antibody Responses against Nonpoliovirus Enteroviruses</article-title><source>mBio</source><year>2022</year><volume>13</volume><elocation-id>e0366021</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.03660-21</pub-id><pub-id pub-id-type="pmid">35038922</pub-id><pub-id pub-id-type="pmcid">PMC8764532</pub-id></element-citation></ref><ref id="B163-idr-17-00061"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Currier</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Strobert</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Kajon</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Madan-Lala</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bochkov</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Gern</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A Polyvalent Inactivated Rhinovirus Vaccine Is Broadly Immunogenic in Rhesus Macaques</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>12838</fpage><pub-id pub-id-type="doi">10.1038/ncomms12838</pub-id><pub-id pub-id-type="pmid">27653379</pub-id><pub-id pub-id-type="pmcid">PMC5036149</pub-id></element-citation></ref><ref id="B164-idr-17-00061"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pyle</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>S.</given-names></name></person-group><article-title>Pre-Clinical Development of a Novel Cross-Protective Rhinovirus Vaccine</article-title><source>Eur. Respir. J.</source><year>2024</year><volume>64</volume><fpage>OA5461</fpage></element-citation></ref><ref id="B165-idr-17-00061"><label>165.</label><element-citation publication-type="webpage"><article-title>APOLLO Therapeutics Pipeline&#8212;Status for All Assets Progressed into Full Development</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.apollotx.com/pipeline/" ext-link-type="uri">https://www.apollotx.com/pipeline/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-14">(accessed on 14 May 2025)</date-in-citation></element-citation></ref><ref id="B166-idr-17-00061"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vardavas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zisis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nikitara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lagou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Aslanoglou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Athanasakis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phalkey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leonardi-Bee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Cost of the COVID-19 Pandemic versus the Cost-Effectiveness of Mitigation Strategies in EU/UK/OECD: A Systematic Review</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><fpage>e077602</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2023-077602</pub-id><pub-id pub-id-type="pmcid">PMC10619092</pub-id><pub-id pub-id-type="pmid">37907290</pub-id></element-citation></ref><ref id="B167-idr-17-00061"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ireland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Segura</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Buchwald</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Moir</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Inhibition of HIV-1 Release by ADAM Metalloproteinase Inhibitors</article-title><source>Front. Microbiol.</source><year>2024</year><volume>15</volume><elocation-id>1385775</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2024.1385775</pub-id><pub-id pub-id-type="pmid">38572241</pub-id><pub-id pub-id-type="pmcid">PMC10987949</pub-id></element-citation></ref><ref id="B168-idr-17-00061"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyame</surname><given-names>P.</given-names></name><name name-style="western"><surname>Togami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Masunaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Begum</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Terasawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Monde</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A Heterocyclic Compound Inhibits Viral Release by Inducing Cell Surface BST2/Tetherin/CD317/HM1.24</article-title><source>J. Biol. Chem.</source><year>2024</year><volume>300</volume><elocation-id>107701</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2024.107701</pub-id><pub-id pub-id-type="pmid">39173946</pub-id><pub-id pub-id-type="pmcid">PMC11419809</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="idr-17-00061-f001" orientation="portrait"><label>Figure 1</label><caption><p>Classification of the EV and RV species linked to illnesses in humans.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="idr-17-00061-g001.jpg"/></fig><fig position="float" id="idr-17-00061-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic of <italic toggle="yes">Enterovirus</italic> capsid organization. VP1&#8211;VP3 subunits, represented as a triangular unit with VP4 underneath, are assembled into pentameric structures to form a complete icosahedral capsid composed of 60 copies of the VP1&#8211;VP4 subunits.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="idr-17-00061-g002.jpg"/></fig><fig position="float" id="idr-17-00061-f003" orientation="portrait"><label>Figure 3</label><caption><p>Schematic of <italic toggle="yes">Enterovirus</italic> translation and proteolysis. The genome is translated into a single polyprotein (P1 to P3) then proteolyzed into four structural proteins and seven non-structural proteins. IRES: internal ribosome entry site. UTR: untranslated region.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="idr-17-00061-g003.jpg"/></fig><fig position="float" id="idr-17-00061-f004" orientation="portrait"><label>Figure 4</label><caption><p><italic toggle="yes">Enterovirus</italic> replicative cycle. The virus attaches to a host receptor (1) and is subsequently internalized (2). A change in pH triggers the uncoating of the virus (3), resulting in the release of its genome. This RNA genome is translated (4) into a single polyprotein, which undergoes proteolysis (5) to produce four structural proteins and seven non-structural proteins. Replication organelles are generated (6), providing a site for RNA replication (7). Newly replicated genomes are assembled with translated structural proteins (8) to form a viral particle. Upon maturation (9), the newly formed viral particle is released (10) from the host cell. RO = replication organelle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="idr-17-00061-g004.jpg"/></fig><fig position="float" id="idr-17-00061-f005" orientation="portrait"><label>Figure 5</label><caption><p>Antiviral candidates targeting EV-D68 and rhinovirus at distinct stages of the viral replicative cycle. Capsid-binding agents and monoclonal antibodies block viral attachment by competitively inhibiting receptor-virus interactions. Viral replication protein inhibitors disrupt polyprotein processing and replication organelle biogenesis by targeting non-structural proteins. Host factor inhibitors impair viral attachment, RO formation, or RNA replication. Each class of inhibitors interferes with critical junctures of the viral life cycle, offering complementary strategies for therapeutic intervention. PI4KIII&#946; = PI 4-kinase-III&#946;, SA = Sialic acid, OSBP = oxysterol-binding protein, ORP4 = OSBP-related protein 4.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="idr-17-00061-g005.jpg"/></fig><table-wrap position="float" id="idr-17-00061-t001" orientation="portrait"><object-id pub-id-type="pii">idr-17-00061-t001_Table 1</object-id><label>Table 1</label><caption><p>Antiviral candidates against EV-D68 and RVs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Class </th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antiviral <break/>Compound</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus <break/>Targeted</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protein<break/>Targeted</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage of<break/>Development</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="top" rowspan="1">Capsid Binders </td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Pleconaril </td><td align="left" valign="top" rowspan="1" colspan="1">RV, EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">VP1 </td><td align="left" valign="top" rowspan="1" colspan="1">Phase II clinical trial for RV, Preclinical for EV-D68</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B79-idr-17-00061" ref-type="bibr">79</xref>,<xref rid="B80-idr-17-00061" ref-type="bibr">80</xref>,<xref rid="B81-idr-17-00061" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Pirodavir </td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">VP1 </td><td align="left" valign="top" rowspan="1" colspan="1">Phase II clinical trial</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B82-idr-17-00061" ref-type="bibr">82</xref>,<xref rid="B83-idr-17-00061" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Pocapavir (V-073) </td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">VP1 </td><td align="left" valign="top" rowspan="1" colspan="1">Preclinical for RV and EV-D68, available for use in emergency treatment of severe neonatal EV-B infections</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B84-idr-17-00061" ref-type="bibr">84</xref>,<xref rid="B85-idr-17-00061" ref-type="bibr">85</xref>,<xref rid="B86-idr-17-00061" ref-type="bibr">86</xref>] </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Quinoline derivative: <break/>Compound 19 </td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">Hydrophobic <break/>pocket of VP1</td><td align="left" valign="top" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B87-idr-17-00061" ref-type="bibr">87</xref>] </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">R856932 <break/>(Tetrazole based) </td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">VP1 </td><td align="left" valign="top" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B88-idr-17-00061" ref-type="bibr">88</xref>] </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Vapendavir </td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">VP1 </td><td align="left" valign="top" rowspan="1" colspan="1">Phase II clinical trial</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B89-idr-17-00061" ref-type="bibr">89</xref>,<xref rid="B90-idr-17-00061" ref-type="bibr">90</xref>]</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Viral replication protein inhibitors </td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Azvudine (FNC *)</td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">3D </td><td align="left" valign="top" rowspan="1" colspan="1">Approved in China for indication other than EV or RV infection </td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B91-idr-17-00061" ref-type="bibr">91</xref>] </td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">EIDD-1931, active form of molnupiravir</td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">3D</td><td align="left" valign="top" rowspan="1" colspan="1">EUA ** by FDA, approved in some countries for other infection than EV and RV</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B92-idr-17-00061" ref-type="bibr">92</xref>,<xref rid="B93-idr-17-00061" ref-type="bibr">93</xref>] </td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Fluoxetine </td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">2C</td><td align="left" valign="top" rowspan="1" colspan="1">FDA approved for indication other than EV or RV infection</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B94-idr-17-00061" ref-type="bibr">94</xref>,<xref rid="B95-idr-17-00061" ref-type="bibr">95</xref>] </td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Guanidine </td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">2C</td><td align="left" valign="top" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B96-idr-17-00061" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Ribavirin</td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">3D </td><td align="left" valign="top" rowspan="1" colspan="1">FDA approved for indication other than EV or RV infection</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B97-idr-17-00061" ref-type="bibr">97</xref>,<xref rid="B98-idr-17-00061" ref-type="bibr">98</xref>,<xref rid="B99-idr-17-00061" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Rupintrivir <break/>(AG7088)</td><td align="left" valign="top" rowspan="1" colspan="1">RV, EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">3C </td><td align="left" valign="top" rowspan="1" colspan="1">Phase II for RV </td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B100-idr-17-00061" ref-type="bibr">100</xref>,<xref rid="B101-idr-17-00061" ref-type="bibr">101</xref>] </td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Telaprevir</td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">2A</td><td align="left" valign="top" rowspan="1" colspan="1">FDA approved for indication other than EV or RV infection</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B102-idr-17-00061" ref-type="bibr">102</xref>,<xref rid="B103-idr-17-00061" ref-type="bibr">103</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">V-7404</td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">3C </td><td align="left" valign="top" rowspan="1" colspan="1">Phase I</td><td align="center" valign="bottom" rowspan="1" colspan="1">[<xref rid="B104-idr-17-00061" ref-type="bibr">104</xref>] </td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Host factors inhibitors</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">CRT0066101, CRT0066051 and XX-050</td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">Protein Kinase D (PKD)</td><td align="left" valign="top" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B105-idr-17-00061" ref-type="bibr">105</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">CUR-N399</td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">PI4KIII&#946;</td><td align="left" valign="top" rowspan="1" colspan="1">Phase I</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B106-idr-17-00061" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">DAS181</td><td align="left" valign="top" rowspan="1" colspan="1">RV, EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">Sialic acid</td><td align="left" valign="top" rowspan="1" colspan="1">Fast Track and Breakthrough Therapy designations by the FDA for indications other than EV or RV infection</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B100-idr-17-00061" ref-type="bibr">100</xref>,<xref rid="B107-idr-17-00061" ref-type="bibr">107</xref>,<xref rid="B108-idr-17-00061" ref-type="bibr">108</xref>] </td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Enviroxime</td><td align="left" valign="top" rowspan="1" colspan="1">RV, EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">PI4KIII&#946;</td><td align="left" valign="top" rowspan="1" colspan="1">Phase II for RV, preclinical for EV-D68</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B109-idr-17-00061" ref-type="bibr">109</xref>,<xref rid="B110-idr-17-00061" ref-type="bibr">110</xref>,<xref rid="B111-idr-17-00061" ref-type="bibr">111</xref>] </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">GSK3923868</td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">PI4KIII&#946;</td><td align="left" valign="top" rowspan="1" colspan="1">Phase I</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B112-idr-17-00061" ref-type="bibr">112</xref>,<xref rid="B113-idr-17-00061" ref-type="bibr">113</xref>,<xref rid="B114-idr-17-00061" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Itraconazole</td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">OSBP, ORP4</td><td align="left" valign="top" rowspan="1" colspan="1">FDA approved for indication other than EV or RV infection</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B115-idr-17-00061" ref-type="bibr">115</xref>,<xref rid="B116-idr-17-00061" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">KRP-A218</td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">PI4KIII&#946;</td><td align="left" valign="top" rowspan="1" colspan="1">Phase I</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B117-idr-17-00061" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1"> SAMHD1 ***</td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">Cellular deoxynucleotide triphosphate (dNTP)</td><td align="left" valign="top" rowspan="1" colspan="1">Preclinical </td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B118-idr-17-00061" ref-type="bibr">118</xref>] </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">Vemurafenib</td><td align="left" valign="top" rowspan="1" colspan="1">RV</td><td align="left" valign="top" rowspan="1" colspan="1">PI4KIII&#946;</td><td align="left" valign="top" rowspan="1" colspan="1">FDA approved for indication other than EV or RV infection</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B119-idr-17-00061" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Antibodies</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">A6-1</td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">VP1</td><td align="left" valign="top" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B120-idr-17-00061" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">EV68-159</td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">VP1, VP3</td><td align="left" valign="top" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B121-idr-17-00061" ref-type="bibr">121</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">EV68-228</td><td align="left" valign="top" rowspan="1" colspan="1">EV-D68</td><td align="left" valign="top" rowspan="1" colspan="1">VP1</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B121-idr-17-00061" ref-type="bibr">121</xref>,<xref rid="B122-idr-17-00061" ref-type="bibr">122</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">14C11</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">ICAM-1</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-idr-17-00061" ref-type="bibr">66</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* 2&#8242;-deoxy-2&#8242;-&#946;-fluoro-4&#8242;-azidocytidine, ** Emergency Use Authorization, *** Sterile alpha motif and histidine-aspartic acid domain-containing protein 1.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>